Champions Oncology (CSBR) S-1 11 May 15 IPO registration Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Jan. 31, 2015
Document Information [Line Items]
Entity Registrant Name	CHAMPIONS ONCOLOGY, INC.
Entity Central Index Key	771856
Entity Filer Category	Smaller Reporting Company
Document Type	S-1
Amendment Flag	FALSE
Document Period End Date	31-Jan-15

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jan. 31, 2015	Apr. 30, 2014	Apr. 30, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$182	$5,891	$9,561
Accounts receivable, net	1,092	1,325	500
Prepaid expenses and other current assets	258	383	315
Total current assets	1,532	7,599	10,376
Restricted cash	163	165	192
Property and equipment, net	469	434	414
Goodwill	669	669	669
Total assets	2,833	8,867	11,651
Current liabilities:
Accounts payable	1,362	981	1,204
Accrued liabilities	598	587	611
Notes Payable, related party	2,000	0
Deferred revenue	2,309	2,091	1,114
Total current liabilities	6,269	3,659	2,929
Warrant liability	610	2,011	1,046
Other Non-current liability	98	0
Total liabilities	6,977	5,670	3,975
Redeemable common stock; $0.001 par value; nil and 31,133,333 contingently puttable common shares outstanding as of April 30, 2014 and 2013, respectively		0	16,882
Stockholders' (deficit) equity:
Common stock, $.001 par value; 125,000,000 shares authorized including redeemable common stock; 70,121,741 and 38,855,003 shares issued and 66,885,741 and 35,643,658 shares outstanding as of April 30, 2014 and 2013, respectively	70	70	39
Treasury stock, at cost, 3,236,000 common shares as of April 30, 2014 and 2013	-1,252	-1,252	-1,252
Additional paid-in capital	45,388	43,259	23,580
Accumulated deficit	-48,350	-38,880	-31,473
Accumulated other comprehensive loss		0	-100
Total stockholders' (deficit) equity	-4,144	3,197	-9,206
Total liabilities and stockholders' (deficit) equity	$2,833	$8,867	$11,651

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jan. 31, 2015	Apr. 30, 2014	Apr. 30, 2013
Common stock, par value (in dollars per share)	$0.00	$0.00	$0.00
Common stock, shares authorized, including redeemable common stock	125,000,000	125,000,000	125,000,000
Common stock, shares issued	70,125,836	70,121,741	38,855,003
Common stock, shares outstanding	66,889,600	66,885,741	35,643,658
Treasury stock, common shares	3,236,236	3,236,236	3,236,000
Redeemable common stock, par value (in dollars per share)		$0.00	$0.00
Redeemable common stock, contingently puttable common shares outstanding		0	31,133,333

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2014	Apr. 30, 2013
Operating revenue:
Personalized oncology solutions	$453	$590	$1,245	$1,834	$2,264	$2,390
Translational oncology solutions	1,376	3,100	4,377	7,258	9,286	5,933
Total operating revenue	1,829	3,690	5,622	9,092	11,550	8,323
Costs and operating expenses:
Cost of personalized oncology solutions	674	614	2,190	2,139	2,731	2,672
Cost of translational oncology solutions	1,301	1,008	3,225	2,585	3,532	2,656
Research and development	1,093	535	3,757	1,614	2,265	1,920
Sales and marketing	1,094	821	3,340	2,160	3,155	2,665
General and administrative	1,086	2,120	3,944	4,476	6,127	4,631
Total costs and operating expenses	5,248	5,098	16,456	12,974	17,810	14,544
Loss from operations	-3,419	-1,408	-10,834	-3,882	-6,260	-6,221
Other income (expense):
Change in fair value of warrant liability	621	846	1,401	-1,202	-965	-74
Other expense	-6	-7	-3	-37	-164	-25
Total other income (expense)	615	839	1,398	-1,239	-1,129	-99
Net loss before income tax expense	-2,804	-569	-9,436	-5,121	-7,389	-6,320
Provision for income taxes	12	5	27	13	17	10
Net loss	($2,816)	($574)	($9,463)	($5,134)	($7,406)	($6,330)
Net loss per common share outstanding, including redeemable common stock, basic and diluted					($0.11)	($0.12)
Weighted average common shares outstanding, including redeemable common stock, basic and diluted					66,863,915	52,046,766
Net loss per common share outstanding, including redeemable common stock, basic (in dollars per share)	($0.04)	($0.01)	($0.14)	($0.08)
Net loss per common share outstanding, including redeemable common stock, diluted (in dollars per share)	($0.05)	($0.02)	($0.16)	($0.08)
Weighted average common shares outstanding, including redeemable common stock, basic (in shares)	66,893,364	66,867,114	66,890,929	66,860,792
Weighted average common shares outstanding, including redeemable common stock, diluted (in shares)	67,245,577	66,867,114	67,243,142	66,860,792

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2014	Apr. 30, 2013
Net loss	($2,816)	($574)	($9,463)	($5,134)	($7,406)	($6,330)
Foreign currency translation adjustment	0	1	0	-23	100	25
Comprehensive loss	($2,816)	($573)	($9,463)	($5,157)	($7,306)	($6,305)

CONSOLIDATED_STATEMENT_OF_CHAN

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERSb EQUITY (DEFICIT) (USD $)	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit during Development Stage [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
In Thousands, except Share data
Balance at Apr. 30, 2012	($5,278)	$38	($1,252)	$21,204	($25,143)	($125)
Balance (in shares) at Apr. 30, 2012		34,529,000	3,236,000
Stock-based compensation	2,376	0	0	2,376	0	0
Exercise of options and warrants	0	0	0	0	0	0
Exercise of options and warrants (in shares)		0	0
Issuance of restricted stock	0	0	0	0	0	0
Issuance of restricted stock (in shares)		50,000	0
Issuance of Anti-Dilutive shares as it relates to 2013 financing	1	1	0	0	0	0
Issuance of Anti-Dilutive shares as it relates to 2013 financing (in shares)		1,064,658	0
Foreign currency translation adjustment	25	0	0	0	0	25
Net loss	-6,330	0	0	0	-6,330	0
Balance at Apr. 30, 2013	-9,206	39	-1,252	23,580	-31,474	-100
Balance (in Shares) at Apr. 30, 2013		35,643,658	3,236,000
Stock-based compensation	2,807	0	0	2,807	0	0
Exercise of options and warrants	21	0	0	21	0	0
Exercise of options and warrants (in shares)		33,750	0
Issuance of restricted stock	0	0	0	0	0	0
Issuance of restricted stock (in shares)		75,000	0
Amendment to Redeemable Stock	16,881	31		16,851
Amendment to Redeemable Stock (in Shares)		31,133,333
Foreign currency translation adjustment	100	0	0	0	0	100
Net loss	-7,406	0	0	0	-7,406	0
Balance at Apr. 30, 2014	$3,197	$70	($1,252)	$43,259	($38,880)	$0
Balance (in Shares) at Apr. 30, 2014		66,885,741	3,236,000

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2014	Apr. 30, 2013
Operating activities:
Net loss	($9,463)	($5,134)	($7,406)	($6,330)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	2,284	1,968	2,807	2,376
Net foreign currency remeasurement loss			124	0
Depreciation expense	166	158	213	203
Change in fair value of warrant liability	-1,401	1,202	965	74
Changes in operating assets and liabilities:
Accounts receivable	233	-2,623	-825	84
Grant receivable			0	0
Prepaid expenses, deposits and other	125	34	-68	-110
Restricted cash	2	28	27	-42
Accounts payable	381	-266	-223	-472
Accrued liabilities	-167	94	-24	-14
Deferred revenue	218	981	977	-71
Net cash used in operating activities	-7,622	-3,558	-3,433	-4,302
Investing activities:
Purchase of property and equipment	-84	-164	-234	-57
Net cash used in investing activities	-84	-164	-234	-57
Financing activities:
Proceeds from executive note financing	2,000	0
Capital lease payments	-5	0
Proceeds from exercise of options and warrants	2	0	21	0
Net cash provided by financing activities	1,997	0	21	9,141
Private placement of commons shares and warrants			0	9,141
Exchange rate effect on cash and cash equivalents	0	-27	-24	25
Decrease in cash and cash equivalents	-5,709	-3,749	-3,670	4,807
Cash and cash equivalents, beginning of period	5,891	9,561	9,561	4,754
Cash and cash equivalents, end of period	182	5,812	5,891	9,561
Non-cash investing activities:
Purchased equipment under capital lease	$124	$0

Organization_Use_of_Estimates_

Organization, Use of Estimates and Basis of Presentation	9 Months Ended													12 Months Ended
	Jan. 31, 2015													Apr. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Organization, Use of Estimates and Basis of Presentation													Note 1. Organization and Basis of Presentation
	Champions Oncology, Inc. (the “Company”), is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Personalized Oncology Solutions (“POS”) and Translational Oncology Solutions (“TOS”). POS assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings.													Background
	The Company has three operating subsidiaries: Champions Oncology (Israel), Limited, Champions Biotechnology U.K., Limited and Champions Oncology Singapore, PTE LTD. For the three and nine months ended January 31, 2015 and 2014, there were no material revenues earned by these subsidiaries.													Champions Oncology, Inc. (the “Company”), is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Personalized Oncology Solutions (“POS”) and Translational Oncology Solutions (“TOS”). POS assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings.
	The Company’s foreign subsidiaries functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations.													The Company has three operating subsidiaries: Champions Oncology (Israel), Limited, Champions Biotechnology U.K., Limited and Champions Oncology Singapore, PTE LTD. For the years ended April 30, 2014 and 2013, there were no material revenues earned by these subsidiaries.
	These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission or the SEC. All significant intercompany transactions and accounts have been eliminated. All figures are presented in thousands of U.S. dollars, except share data, or except where expressly stated otherwise. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States or GAAP has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended April 30, 2014, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Annual Report on Form 10-K for the year ended April 30, 2014.													Basis of Presentation
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.													The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
	Reclassification
	Certain prior year amounts have been reclassified to conform to the current year presentation.
	Earnings Per Share
	Basic net loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock plus dilutive potential common stock considered outstanding during the period. Such dilutive shares consist of incremental shares that would be issued upon exercise of the Company’s derivative warrants.
		Three Months Ended						Nine Months Ended
		January 31,						January 31,
		2015			2014			2015			2014
	Basic loss per share computation
	Net loss attributable to common stockholders	$	(2,816,465	)	$	(574,207	)	$	(9,462,281	)	$	(5,133,684	)
	Weighted Average common shares - basic		66,893,364			66,867,114			66,890,929			66,860,792
	Basic net loss per share	$	(0.04	)	$	(0.01	)	$	(0.14	)	$	(0.08	)
	Diluted loss per share computation
	Net loss attributable to common stockholders	$	(2,816,465	)	$	(574,207	)	$	(9,462,281	)	$	(5,133,684	)
	Less: Gain on derivative warrant liability		620,687			845,774			1,401,314			-
	Loss available to common stockholders	$	(3,437,152	)	$	(1,419,981	)	$	(10,863,595	)	$	(5,133,684	)
	Weighted Average common shares		66,893,364			66,867,114			66,890,929			66,860,792
	Incremental shares from assumed exercise of warrants and stock options		352,213			-			352,213			-
	Adjusted weighted average share - diluted		67,245,577			66,867,114			67,243,142			66,860,792
	Diluted net loss per share	$	(0.05	)	$	(0.02	)	$	(0.16	)	$	(0.08	)
	The following table reflects the total potential share-based instruments outstanding at January 31, 2015 and 2014 that could have an effect on the future computation of dilution per common share:
		January 31,
		2015			2014
	Stock options		23,990,008			22,633,955
	Warrants		3,126,667			3,276,667
	Total common stock equivalents		27,116,675			25,910,622
	Liquidity
	Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. In the past, we have met these cash requirements through our sales of products and services, cash and cash equivalents, working capital management, and proceeds from certain private placements of our securities. As of January 31, 2015, we had negative working capital of $4.7 million and cash and cash equivalents on hand of $0.2 million.
	On March 11, 2015, the Company entered into a 2015 Securities Purchase Agreement with related party and non-related party investors for the sale to the investors of 35,271,052 units, each unit consisting of one share of the Company's common stock, par value $0.001 per share, and a warrant to buy 0.55 shares of common stock at $0.48 per share, at a purchase price of $0.40 per unit, for an aggregate of approximately $14,000,000 ( net proceeds of approximately $13,000,000, which includes the conversion of $2 million in convertible notes issued in December 2014). This transaction closed on March 13, 2015. See Note 10 for more detail.
	As of March 17, 2015, Management believes that the Company has sufficient cash on hand to continue as a going concern for the at least the next 12 months.
	Provision for Income Taxes
	Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements. As of January 31, 2015 and 2014, the Company provided a valuation allowance for all net deferred tax assets, as it is not more likely than not that the assets will not be recovered based on an insufficient history of earnings.
	The income tax provision for the nine months ended January 31, 2015 was $27 as compared to $13 for the corresponding period in the previous year, and primarily consists of income tax obligations payable to the foreign jurisdictions.
	There were no uncertain tax position identified by the Company.

Recently_Issued_Accounting_Pro

Recently Issued Accounting Pronouncements	9 Months Ended
	Jan. 31, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	Note 2. Recently Issued Accounting Pronouncements
	In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers”, which will replace most existing revenue recognition guidance in U.S. Generally Accepted Accounting Principles and is intended to improve and converge with international standards the financial reporting requirements for revenue from contracts with customers. The core principle of ASU 2014-09 is that an entity should recognize revenue for the transfer of goods or services equal to the amount that it expects to be entitled to receive for those goods or services. ASU 2014-09 also requires additional disclosures about the nature, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments. ASU 2014-09 allows for both retrospective and prospective methods of adoption and is effective for periods beginning after December 15, 2016. The Company is currently evaluating the impact that the adoption of ASU 2014-09 will have on our financial statements.
	In June 2014, FASB has issued Accounting Standards Update (“ASU”) No. 2014-12, “Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. This ASU requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered.. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated balance sheets and results of operations.
	In August 2014, FASB issued Accounting Standards Update (“ASU”) 2014-15, “Presentation of Financial Statements — Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This ASU requires management to evaluate, in connection with preparing financial statements for each annual and interim reporting period, whether there are conditions or events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable) and provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2014-15 on its financial statements.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Apr. 30, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2. Summary of Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
	The Company’s foreign subsidiaries, functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with a maturity of three months or less at the time of purchase, to be cash equivalents. At various times, the Company has amounts on deposit at financial institutions in excess of federally insured limits.
	Fair Value
	The carrying value of cash and cash equivalents, accounts receivable, prepaid expenses, deposits and other receivables, accounts payable, and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:
	·             Level one — Quoted market prices in active markets for identical assets or liabilities;
	·            Level two — Inputs other than level one inputs that are either directly or indirectly observable; and
	·            Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.
	Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company has one liability measured at fair value on a recurring basis, which are warrants that were issued in connection with private placements of the Company’s securities that are discussed more fully in Note 6. As of April 30, 2014 and 2013, these warrants had an estimated fair value of $2,011,000 and $1,046,000, respectively, which was calculated by the Monte Carlo simulation valuation method using level three inputs. The Company has no assets that are measured at fair value on a recurring basis and there were no assets or liabilities measured at fair value on a non-recurring basis during the years ended April 30, 2014 and 2013.
	The following table presents information about our warrant liability, which was our only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of April 30 (dollars in thousands):
			2014		2013
	Balance beginning of year		$	-1,046	$	-555
	Transfers to (from) Level 3			-		-
	Total gains (losses) included in earnings			-965		-74
	Issuances			-		-417
	Balance end of year		$	-2,011	$	-1,046
	Accounts Receivable
	Accounts receivable represent amounts due under agreements with pharmaceutical and biotechnology companies for TOS and amounts due under agreements with patients for POS. At each reporting period, the Company evaluates open accounts receivable for collectability and records an allowance for potentially uncollectible accounts. As of April 30, 2014 and 2013, the allowance for these accounts was $2,000 and $19,000, respectively. Accounts receivable is also comprised of certain unbilled accounts receivable for services completed under TOS that have not been billed as of the balance sheet date. As of April 30, 2014 and 2013, the Company had unbilled receivables of $884,000 and $200,000, respectively.
	Restricted Cash
	As of April 30, 2014 and 2013, the Company has restricted cash of $165,000 and $192,000, respectively, which is classified as a noncurrent asset on the consolidated balance sheets. This restricted cash serves as collateral for corporate credit cards to provide financial assurance that the Company will fulfill its obligations. The cash is held in custody by the issuing bank, is restricted as to withdrawal or use, and is currently invested in an interest-bearing Certificate of Deposit (“CD”). Though the CD matures in the second quarter of fiscal 2015, the cash will be reinvested into another CD to continue use of the corporate cards. The Company accounts for this CD as a non-current asset supporting operations of the business.
	Property and Equipment
	Property and equipment is recorded at cost and primarily consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following (in thousands):
			April 30,
			2014		2013
	Furniture and fixtures		$	69	$	59
	Computer equipment and software			655		549
	Laboratory equipment			296		179
	Leasehold improvements			2		2
	Total property and equipment			1,022		789
	Less: Accumulated depreciation			-588		-375
	Property and equipment, net		$	434	$	414
	Depreciation expense was $213,000 and $203,000 for the years ended April 30, 2014 and 2013, respectively.
	Impairment of Long-Lived Assets
	Impairment losses are to be recognized when the carrying amount of a long-lived asset is not recoverable or exceeds its fair value.  The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that a carrying value may not be recoverable.  The Company uses estimates of future cash flows over the remaining useful life of a long- lived asset or asset group to determine the recoverability of the asset.  These estimates only include the net cash flows directly associated with, and that are expected to arise as a direct result of, the use and eventual disposition of the asset or asset group.  The Company has not recognized any impairment losses for the Company’s long-lived assets for the years ending April 30, 2014 and 2013.
	Goodwill
	Goodwill represents the excess of the cost over the fair market value of the net assets acquired including identifiable assets. Goodwill is tested annually, or more frequently if circumstances indicate potential impairment, by comparing its fair value to its carrying amount. The determination of whether or not goodwill is impaired involves significant judgment. Although the Company believes its goodwill is not impaired, changes in strategy or market conditions could significantly impact the judgments and may require future adjustments to the carrying value of goodwill. The Company uses a two-step process to test for goodwill impairment. The first step is to screen for potential impairment, while the second step measures the amount of the impairment, if any. The first step of the goodwill impairment test compares the fair value of each reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired. If the carrying value of the reporting unit’s net assets, including goodwill, exceeds the fair value of the reporting unit, then the Company determines the implied fair value of goodwill. If the carrying value of goodwill exceeds its implied fair value, then an impairment of goodwill has occurred and an impairment loss would be recognized for the difference between the carrying amount and the implied fair value of goodwill as a component of operating income. The implied fair value of goodwill is calculated by subtracting the fair value of tangible and intangible assets associated with the reporting unit from the fair value of the unit. The Company tests for goodwill impairment at the operating segment level.
	The Company has not recognized any impairment losses for the Company’s goodwill for the years ending April 30, 2014 and 2013.
	Deferred Revenue
	Deferred revenue represents payments received in advance for products to be delivered.  When products are delivered, deferred revenue is then recognized as earned.
	Warrant Liability
	Warrant liability represents the fair value of warrants issued in connection with private placements of the Company’s common stock, which are described more fully in Note 7. These warrants are presented as liabilities based on the certain exercise price reset provisions.  The liability, which is recorded at fair value on the accompanying consolidated balance sheets, is calculated by the Monte Carlo simulation valuation method.  The change in fair value of these warrants is recognized as other income or expense in the consolidated statements of operations.
	Revenue Recognition
	The Company derives revenue from its POS and TOS businesses. Personalized oncology solutions assist physicians by providing information to help guide the development of personalized treatment plans for their patients using our core offerings, including testing oncology drugs and drug combinations on personalized TumorGrafts, and through other products. Translational oncology solutions offer a preclinical TumorGraft platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings. The Company recognizes revenue when the following four basic criteria are met: (i) a contract has been entered into with its customers; (ii) delivery has occurred or services rendered to its customers; (iii) the fee is fixed and determinable as noted in the contract; and (iv) collectability is reasonably assured. The Company utilizes a proportional performance revenue recognition model for its TOS business, under which it recognizes revenue as performance occurs, based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement, typically the delivery of reports to its customers documenting the results of testing protocols.
	When a POS or TOS arrangement involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. The Company performs this evaluation at the inception of an arrangement and as each item in the arrangement is delivered. Generally, the Company accounts for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) has standalone value to the customer, and (ii) if the Company has given the customer a general right of return relative to the delivered item(s) and the delivery or performance of the undelivered item(s) or service(s) is probable and substantially in the Company’s control. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or if there is no predominant deliverable upon delivery of the final element of the arrangement.
	During the third quarter of fiscal year 2014 we entered into a contract that may require the replacement of licensed tumors in the event that certain contractual terms have not been satisfied. Due to such requirements we have estimated an amount of licensed tumors that may need to be replaced, and we have deferred this revenue until all provisions of the agreement have been met. There was $258,000 of deferred revenue as of April 30, 2014 relating to our estimate of replacement of licensed tumors.
	Cost of Personalized Oncology Solutions
	Cost of POS consists of costs related to POS revenue earned from implantations, drug panels, tumor boards, and gene sequencing services, as well as indirect internal costs, such as salaries for personnel directly engaged in these products. Direct costs associated with implantation revenues are primarily related to mice purchases and maintenance and shipping of tumor tissue. Direct drug panel costs are primarily incurred from mice purchases and maintenance and drug purchases. Direct tumor board costs are primarily related to physicians’ honorariums and any tumor board participation costs such as travel, lodging and meals. Direct gene sequencing costs are primarily related to costs billed from the gene sequencing service provider. All costs are expensed as incurred.
	Cost of Translational Oncology Solutions
	Cost of TOS consists of costs related to TOS revenue. Direct costs include mice purchases and maintenance costs for studies completed internally and charges from CROs for studies handled externally. Indirect costs include salaries for personnel directly engaged in providing TOS products. All costs of performing studies in-house are expensed as incurred.
	Research and Development
	Research and development costs represent both costs incurred internally for research and development activities, including personnel costs and mice purchases and maintenance, as well as costs incurred externally to facilitate research activities, such as tumor tissue procurement and characterization expenses.  All research and development costs are expensed as incurred. .
	Sales and Marketing
	Selling and marketing expenses represent costs incurred to promote the Company’s products offered, including salaries, benefits and related costs of our sales and marketing personnel, and represent costs of advertising and other selling and marketing expenses. All sales and marketing costs, including advertising costs, are expensed as incurred.
	Basic and Dilutive Loss Per Common Share
	Basic loss per share is calculated by dividing loss available to common shareholders by the weighted average number of common shares (including redeemable common stock) outstanding for the year.  Diluted loss per share is calculated based on the weighted average number of common shares (including redeemable common stock) outstanding for the year, plus the dilutive effect of common stock purchase warrants, stock options and restricted stock units using the treasury stock method.  Contingently issuable shares are included in the calculation of basic earnings per share when all contingencies surrounding the issuance of the shares are met and the shares are issued or issuable.  Contingently issuable shares are included in the calculation of dilutive earnings per share as of the beginning of the reporting period if, at the end of the reporting period, all contingencies surrounding the issuance of the shares are satisfied or would be satisfied if the end of the reporting period were the end of the contingency period.  Due to the net losses for the years ended April 30, 2014 and 2013, basic and diluted loss per share were the same, as the effect of potentially dilutive securities (as listed below) would have been anti-dilutive.
	The following table reflects the total potential share-based instruments outstanding at April 30, 2014 and 2013, that could have an effect on the future computation of dilution per common share:
			Year Ended April 30,
			2014		2013
	Stock options			23,351,037		13,890,205
Warrants			3,276,667		3,276,667
Restricted stock			-		50,000
Total common stock equivalents			26,627,704		17,216,872
Share-Based Payments
The Company typically recognizes expense for share-based payments based on the fair value of awards on the date of grant. The Company uses the Black-Scholes option pricing model to estimate fair value. The Black-Scholes option valuation model was developed for use in estimating the fair value of short-traded options that have no vesting restrictions and are fully transferable. The option pricing model requires the Company to estimate certain key assumptions such as expected life, volatility, risk free interest rates and dividend yield to determine the fair value of share-based awards. These assumptions are based on historical information and management judgment. The risk-free interest rate used is based on the United States treasury security rate with a term consistent with the expected term of the award at the time of the grant. Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the Securities and Exchange Commission-approved “simplified method” noted under the provisions of Staff Accounting Bulletin No. 107 with the continued use of this method extended under the provisions of Staff Accounting Bulletin No. 110. During fiscal 2013, the Company changed its method used to calculate expected volatility from an index, which was based on the Company’s historic volatility and certain comparable guideline companies, to the use of only the Company’s historic volatility which had an immaterial effect on the financial statements. The Company does not anticipate paying a dividend, and therefore, no expected dividend yield was used.
The Company expenses share-based payments over the period that the awards are expected to vest, net of estimated forfeitures. If actual forfeitures differ from management’s estimates, compensation expense is adjusted. The Company will report cash flows resulting from tax deductions in excess of the compensation cost recognized from those options (excess tax benefits) as financing cash flows, if they should arise.
Income Taxes
Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements.  In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is not likely or there is insufficient operating history, a valuation allowance is established.  The Company adjusts the valuation allowance in the period management determines it is more likely than not that net deferred tax assets will or will not be realized.  As of April 30, 2014 and 2013, the Company provided a valuation allowance for all net deferred tax assets, as recovery is not more likely than not based on an insufficient history of earnings.
Tax positions are positions taken in a previously filed tax return or positions expected to be taken in a future tax return that are reflected in measuring current or deferred income tax assets and liabilities reported in the consolidated financial statements.  Tax positions include, but are not limited to, the following:
	·	An allocation or shift of income between taxing jurisdictions;
	·	The characterization of income or a decision to exclude reportable taxable income in a tax return; or
	·	A decision to classify a transaction, entity or other position in a tax return as tax exempt.
The Company reflects tax benefits only if it is more likely than not that we will be able to sustain the tax position, based on its technical merits. If a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized. The Company has no unrecognized tax benefits as of April 30, 2014 and 2013.
The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company’s balance sheets at April 30, 2013 and 2012, and has not recognized interest and/or penalties in the statement of operations for either period.
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09 Revenue from Contracts with Customers (Topic 606). This guidance is intended to improve and converge with international standards the financial reporting requirements for revenue from contracts with customers. It will be effective for our first quarter of fiscal year 2018 and early adoption is not permitted. We have not yet determined the impact from adoption of this new accounting pronouncement on our financial statements.

Property_and_Equipment

Property and Equipment	9 Months Ended
	Jan. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 3. Property and Equipment
	Property and equipment is recorded at cost and consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following (in thousands):
		January 31,			April 30,
		2015			2014
		(unaudited)
	Furniture and fixtures	$	70		$	69
	Computer equipment and software		694			655
	Laboratory equipment		457			296
	Leasehold improvements		2			2
	Total property and equipment		1,223			1,022
	Less: Accumulated depreciation		-754			-588
	Property and equipment, net	$	469		$	434
	Depreciation expense was $52 and $56 for the three months ended January 31, 2015 and 2014, respectively, and $166 and $158 for the nine months ended January 31, 2015 and 2014, respectively. As of January 31, 2015 and April 30, 2014, property, plant and equipment included assets held under capital lease of $124 and $0, respectively. Related depreciation expense was $6 and $0, respectively.
	Capital Lease
	In November 2014, the Company entered into a lease for laboratory equipment. The lease is a capital lease that has costs of approximately $149 through November 2019. The current monthly capital lease payment is approximately $3.
	The following is a schedule by years of future minimum lease payments under this capital lease together with the present value of the net minimum lease payments as of January 31, 2015:
	For the Years Ended April 30,	2015		$	6
		2016			23
		2017			24
		2018			25
		2019			26
		2020			16
	Total minimum lease payments			$	120
	Less: current maturity				-22
	Long-term maturity				98
	The present value of minimum future obligations shown above is calculated based on interest rate of 5%.

ShareBased_Payments

Share-Based Payments	9 Months Ended														12 Months Ended
	Jan. 31, 2015														Apr. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 4. Share-Based Payments														Note 7. Share-Based Payments
	The Company has in place a 2010 Equity Incentive Plan and a 2008 Equity Incentive Plan. In general, these plans provide for stock-based compensation in the form of (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.														Stock-based compensation in the amount of $2.8 million and $2.4 million was recognized for years ended April 30, 2014 and 2013, respectively.   Stock-based compensation costs were recorded as follows (in thousands):
	Stock-based compensation in the amount of $657 and $941 was recognized for the three months ended January 31, 2015 and 2014, respectively and $2,284 and $1,968 for the nine months ended January 31, 2015 and 2014, respectively.  As of January 31, 2015, $158 of stock compensation is included within accrued liabilities line item on the balance sheet. Stock-based compensation expense was recognized as follows (in thousands):															Year Ended April 30,
																2014		2013
		Three Months Ended						Nine Months Ended
		January 31,						January 31,							General and administrative	$	2,298	$	1,984
		2015			2014			2015			2014				Sales and marketing		352		263
															Research and development		36		37
	General and administrative	$	474		$	866		$	1,530		$	1,686			TOS cost of sales		56		20
	Sales and marketing		114			63			447			189			POS cost of sales		65		72
	Research and development		65			4			267			19
	TOS cost of sales		2			2			20			12			Total stock-based compensation expense	$	2,807	$	2,376
	POS cost of sales		2			6			20			62
															2010 Equity Incentive Plan
	Total stock-based compensation expense	$	657		$	941		$	2,284		$	1,968
															On February 18, 2011, shareholders owning a majority of the issued and outstanding shares of the Company executed a written consent approving the 2010 Equity Incentive Plan (“2010 Equity Plan”). The purpose of the 2010 Equity Plan is to grant (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees. Total stock awards under the 2010 Equity Plan shall not exceed 30,000,000 shares of common stock. Options and Stock Appreciation Rights expire no later than ten years from the date of grant and the awards vest as determined by the Board of Directors. Options and Stock Appreciation Rights have a strike price not less than 100% of the fair market value of the common stock subject to the option or right at the date of grant.
	Stock Option Grants
															2008 Equity Incentive Plan
	Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2015 and 2014 were as follows (in thousands):
															The Company has previously granted (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees under a 2008 Equity Incentive Plan (the “2008 Equity Plan”).  Such awards may be granted by the Company’s Board of Directors.  Options granted under the 2008 Equity Plan expire no later than ten years from the date of grant and the awards vest as determined by the Board of Directors.
		Three Months Ended				Nine Months Ended
		January 31,				January 31,									For share-based payments to non-employee consultants under both the 2010 and 2008 Equity Incentive Plan, the fair value of the share-based consideration issued is used to measure the transaction, as management believes this to be a more reliable measure of fair value than the services received.  The fair value of the award is expensed over the period service is provided to the Company; however, it is ultimately measured at the price of the Company’s common stock or the fair value of stock options using the Black-Scholes valuation model on the date that the commitment for performance by the non-employee consultant has been reached or performance is complete, which is generally the vesting date of the award.
		2015		2014		2015		2014
															Director Compensation Plan
	Expected term in years	-		6-May		6-Mar		6-May
	Risk-free interest rates	-		1.4% - 2.1%		0.79% - 1.94%		0.8% - 2.4%							On December 12, 2013, the Compensation Committee of the Board of Directors of the Company adopted changes to the Director Compensation Plan of 2010 (the “Director Plan”) effective commencing December 1, 2013.  Under the Director Plan, independent directors of the Company are entitled to an annual award of a five-year option to purchase 100,000 shares of the Company’s common stock, and the Chairman of the Board of the Company is entitled to an annual award of a five year option to purchase 200,000 shares of the Company’s common stock.  Independent directors who serve as chairperson of a committee will also receive an annual grant of a five-year option to purchase 20,000 shares of the Company’s unregistered common stock. All options issued under the Director Plan vest quarterly at a rate of 25%. Option grants will typically be issued after the annual shareholder meeting which will generally be held in September of each year. New directors will receive a grant upon joining the Board equal to the pro-rata annual grant for the remainder of the year.
	Volatility	-		97% - 102%		85.8% - 102.1%		97% - 102%
	Dividend yield	-		0%		0%		0%							Stock Option Grants
	The weighted average fair value of stock options granted during the three months ended January 31, 2015 and 2014 was nil and $0.97, respectively. The weighted average fair value of stock options granted during the nine months ended January 31, 2015 and 2014 was $0.67 and $0.96, respectively. The Company’s stock options activity for the nine months ended January 31, 2015 is as follows:														Black-Scholes assumptions used to calculate the fair value of options granted during the years ended April 30, 2014 and 2013 were as follows:
											Weighted					Year Ended April 30,
								Weighted			Average					2014		2013
				Directors				Average			Remaining		Aggregate
		Non-		and				Exercise			Contractual		Intrinsic		Expected term in years		3.0 - 6.0		3.0 - 6.0
		Employees		Employees		Total		Price			Life (Years)		Value		Risk-free interest rates		0.7% - 2.4%		0.7% - 1.3%
															Volatility		84% - 102%		88% - 104%
	Outstanding, May 1, 2014	765,000		22,586,037		23,351,037		$	1.01		7.5		$	985	Dividend yield		0%		0%
	Granted	80,000		1,013,175		1,093,175			0.72		5.9			-
	Exercised	-		-3,750		-3,750			0.49						The weighted average fair value of stock options granted during the years ending April 30, 2014 and 2013, was $0.96 and $0.41, respectively. The Company’s stock options activity and related information as of and for the years ended April 30, 2014 and 2013 is as follows (dollars in thousands):
	Forfeited	-		-101,250		-101,250			0.96
	Expired	-150,000		-199,204		-349,204			1.04															Weighted
																						Weighted		Average
	Outstanding, January 31, 2015	695,000		23,295,008		23,990,008			1		6.6			63				Directors				Average		Remaining		Aggregate
																Non-		and				Exercise		Contractual		Intrinsic
	Vested and expected to vest as of January 31, 2015	695,000		23,295,008		23,990,008			1		6.6			63		Employees		Employees		Total		Price		Life (Years)		Value
	Exercisable as of January 31, 2015	487,500		16,544,466		17,031,966			0.91		5.8			62	Outstanding, May 1, 2013		765,000		13,125,205		13,890,205	$	0.85		7	$	89,000
															Granted		-		9,793,332		9,793,332		1.23
	Included in the beginning balances outstanding in the table above are 3,000,000 options granted to the Company’s Chief Executive Officer and President which vest based on service criteria and 3,000,000 options granted to the Company’s Chief Executive Officer and President which vest based on performance criteria.  The service-based conditions of these options provide for vesting to occur monthly over a period of three years.  Since the straight-line method is not available for performance or market-based share-based payments, the 3,000,000 performance-based options will be expensed on an accelerated basis once the Company determines it is probable that the performance-based conditions will be met.														Exercised		-		-33,750		-33,750		0.63
															Canceled		-		-		-		-
	Stock Purchase Warrants														Forfeited		-		-72,500		-72,500		0.82
															Expired		-		-226,250		-226,250		0.73
	As of January 31, 2015 and April 30, 2014, the Company had warrants outstanding for the purchase of 3,276,667 shares of its common stock, all of which were exercisable. Of these warrants, 1,266,667 were issued in connection with the April 2011 Private Placement and 1,860,000 were issued in connection with the January 2013 Private Placement and are accounted for as liabilities. The remaining 150,000 warrants, with an exercise price of $1.00, were accounted for as equity instruments and expired on July 31, 2014. Activity related to these warrants, which expire at various dates through April 2016, is summarized as follows (dollars in thousands):
															Outstanding, April 30, 2014		765,000		22,586,037		23,351,037		1.01		7.5	$	985,000
							Weighted
				Weighted			Average								Vested and expected to vest as of April 30, 2014		765,000		22,586,037		23,351,037				7.5	$	985,000
		Number		Average			Remaining		Aggregate
		of		Exercise			Contractual		Intrinsic						Exercisable as of April 30, 2014		522,292		13,042,285		13,564,577		0.85		6.1	$	927,000
		Shares		Price			Life (Years)		Value
	Outstanding, May 1, 2014	3,276,667		$	0.61		2.9		$	984														Weighted
	Granted	-			-		-			-												Weighted		Average
	Exercised	-			-		-			-								Directors				Average		Remaining		Aggregate
	Expired	-150,000			-		-			-						Non-		and				Exercise		Contractual		Intrinsic
																Employees		Employees		Total		Price		Life (Years)		Value
	Outstanding, January 31, 2015	3,126,667		$	0.6		2.3		$	-
															Outstanding, May 1, 2012		1,410,000		13,456,038		14,866,038	$	0.88		7.6	$	-
The warrants issued in connection with both the April 2011 Private Placement and January 2013 Private Placement contain certain exercise price reset provisions. Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its Common Stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the April 2011 Private Placement and January 2013 Private Placement). These exercise price reset provisions resulted in a downward adjustment to the exercise price of the warrants issued in the April 2011 Private Placement from $0.90 to $0.50.														Granted		130,000		611,250		741,250		0.41
														Exercised		-		-		-		-
The Company has accounted for the warrants issued in connection with the April 2011 Private Placement and January 2013 Private Placement as a liability based on the exercise price reset provisions described above. This liability, which is recorded at fair value on the accompanying consolidated balance sheets, totaled $0.8 million at the time of the close of the January 2013 Private Placement Agreement. As of January 31, 2015 and April 30, 2014, the fair value of these warrants was $0.6 million and $2.01 million, respectively. The change in fair value of these warrants has been, and will be, recognized as other income (expense) on the Company’s consolidated statements of operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. Assumptions used to calculate the fair value of these warrants were as follows:														Canceled		-		-25,000		-25,000		0.62
														Forfeited		-		-551,250		-551,250		0.72
	January 31,		April 30,											Expired		-775,000		-365,833		-1,140,833		0.95
	2015		2014
														Outstanding, April 30, 2013		765,000		13,125,205		13,890,205		0.85		7	$	89,000
Expected term in years	1.2 - 3.0		1.9 - 3.7
Risk-free interest rates	0.6% - 1.05%		0.4% - 1.17%											Vested and expected to vest as of April 30, 2013		765,000		13,125,205		13,890,205				7	$	89,000
Volatility	73% - 100%		95% - 113%
Dividend yield	0%		0%											Exercisable as of April 30, 2013		458,334		10,886,120		11,344,454		0.86		6.9	$	54,000
The Company estimated the volatility based upon the applicable look-back periods or historical volatility observed for the Company. For the Risk-free rate the Company used the yield on a T-bill with maturity closest to the expected time to the warrant expiration.														Included in the balances outstanding in the table above are 3,000,000 options (which vest based on service criteria) granted to the Company’s Chief Executive Officer and its President as of November 5, 2013 as part of their new employment agreements. In addition to the above, there are 3,000,000 additional options granted to the Company’s Chief Executive Officer and President which vest based on both service and performance criteria.  The service-based conditions of these options provide for vesting to occur monthly over a period of three years.  The service-based options, like all of the Company’s service-based options, are expensed on a straight-line basis.  Since the straight-line method is not available for performance or market-based share-based payments, the 3,000,000 performance-based options will be expensed on an accelerated basis once the Company determines it is probable that the performance-based conditions will be met.
In addition to the assumptions above, the Company also takes into consideration whether or not the Company would participate in another round of financing and if that financing is registered or not and what that stock price would be for the financing at that time.														Restricted Stock Grants
The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants.														A summary of the activity related to restricted stock grants for the years ended April 30, 2014 and 2013 is as follows (dollars in thousands):
The Company has granted demand registration rights in connection with the investment in common shares and the common shares underlying the warrants for both the April 2011 Private Placement and January 2013 Private Placement. These rights include the requirement of the Company to file certain registration statements within a specified time period and to have these registration statements declared effective within a specified time period. If the Company is not able to comply with these registration requirements, the Company will be required to pay cash penalties equal to 1.0% of the aggregate Purchase Price paid by the investors for each 30-day period in which a Registration Default, as defined in the Securities Purchase Agreement, exists. These penalties are subject to a 10% limit of the aggregate Purchase Price paid by the investors. The Company may become subject to these penalty provisions if it fails to have a registration statement for the common shares declared effective, or to maintain the effectiveness of such registration statement. The total amount of potential penalties under this registration payment arrangement ranges from $50 to $130 for each 30-day period in which a registration default exists; however, as of January 31, 2015 and April 30, 2014, and through the date of this filing, the Company does not believe these penalties to be probable and accordingly, has not established an accrual for such registration payment arrangements.															2014				2013
																	Weighted				Weighted
																	Average				Average
																	Grant Date				Grant Date
															Total		Fair Value		Total		Fair Value
															Shares		Per Share		Shares		Per Share
														Nonvested, beginning of period		50,000	$	0.3		25,000	$	0.75
														Granted		-		-		100,000		0.3
														Vested		-50,000		0.3		-75,000		0.45
														Forfeited		-		-		-
														Expired		-		-		-
														Nonvested, end of period		-		-		50,000		0.3
														The total fair value of shares vested during the years ended April 30, 2014 and 2013 was $15,000 and $34,000, respectively. As of April 30, 2014, there was no unrecognized stock compensation expense related to nonvested restricted stock awards.
														Stock Purchase Warrants
														As of April 30, 2014, the Company had warrants outstanding for the purchase of 3,276,667 shares of its common stock, all of which were exercisable. Of these warrants, 1,266,667 were issued in connection with the April 2011 Private Placement and 1,860,000 were issued in connection with the January 2013 Private Placement and are accounted for as liabilities as further discussed in Note 7. The remaining 150,000 warrants are accounted for as equity instruments and expire July 31, 2014. Activity related to these warrants, which expire at various dates through April 2016, is summarized as follows (dollars in thousands):
																			Weighted
																	Weighted		Average
															Number		Average		Remaining		Aggregate
															of		Exercise		Contractual		Intrinsic
															Shares		Price		Life (Years)		Value
														Outstanding, May 1, 2013		3,276,667	$	0.61		3.9	$	-
														Granted		-		-		-
														Exercised		-		-
														Forfeited		-		-
														Expired		-		-
														Outstanding, April 30, 2014		3,276,667	$	0.61		2.9	$	984,333
																			Weighted
																	Weighted		Average
															Number		Average		Remaining		Aggregate
															of		Exercise		Contractual		Intrinsic
															Shares		Price		Life (Years)		Value
														Outstanding, May 1, 2012		1,416,667	$	0.5		3.8	$	-
														Granted		1,860,000		0.66		4.8
														Exercised		-		-
														Forfeited		-		-
														Expired		-		-
														Outstanding, April 30, 2013		3,276,667	$	0.61		3.9	$	-

Related_Party_Transactions

Related Party Transactions	9 Months Ended	12 Months Ended
	Jan. 31, 2015	Apr. 30, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 5. Related Party Transactions	Note 10. Related Party Transactions
	Related party transactions include transactions between the Company and its shareholders, management, or affiliates.  The following transactions were in the normal course of operations and were measured and recorded at the exchange amount, which is the amount of consideration established and agreed to by the parties.	Related party transactions include transactions between the Company and its shareholders, management, or affiliates.  The following transactions were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.
	Consulting Services	Consulting Services
	During the nine months ended January 31, 2015 and 2014, the Company paid a member of its Board of Directors $75 and $115, respectively, for consulting services unrelated to his duties as a board member. All of the amounts paid to this related party have been recognized and expensed in the period the services were performed.	During the years ended April 30, 2014 and 2013, the Company paid certain members of its Board of Directors $150,000 and $160,000, respectively, for consulting services unrelated to their duties as board members. During the years ended April 30, 2014 and 2013, the Company paid a substantial stockholder and former member of its Board of Directors $2,000 and $3,000, respectively, for consulting services. During the year ended April 30, 2014, the Company paid a board member’s company $15,800 for consulting services All of the amounts paid to and received from these related parties have been recognized in revenue and expensed in the period the services were performed.
	Notes Payable	Private Placement
	On December 1, 2014, the Company entered into note purchase agreements with and issued convertible promissory notes in the principal amount of $1 million each to Joel Ackerman, the Company’s Chief Executive Officer, and Dr. Ronnie Morris, the Company’s President, to finance the operations of the Company. The transaction was approved by the Company’s audit committee.	During the year ended April 30, 2013, the Company sold an aggregate of 1,000,000 shares of common stock at a price of $0.50 per share and warrants to purchase an aggregate of 100,000 additional shares of common stock at an exercise price of $0.66 per share to two of its officers and directors in the January 2013 Private Placement described in Note 7 above.
	The notes bear interest at 12% per annum and have a term of 90 days. The notes, including any accrued but unpaid interest, are convertible at the option of each noteholder: (a) upon the closing of any equity financing that occurs during the term of the notes, into the securities offered in the financing to other investors at a 5% discount to the price per share paid by other investors in the financing; and (b) upon the maturity date of the notes, into the Company’s common stock at the volume weighted average closing price of the common stock for the five trading days prior to such conversion.
	On February 28, 2015, the Company entered into amendments to the convertible promissory notes issued on December 1, 2014. The amendments extended the maturity dates of the convertible promissory notes to April 1, 2015. The amendments were approved by the Company’s audit committee.
	On March 13, 2015, the convertible promissory notes were converted into equity as part of the 2015 Securities Purchase Agreement. See Note 10 for further details.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended			12 Months Ended
	Jan. 31, 2015			Apr. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 6. Commitments and Contingencies			Note 5. Commitments and Contingencies
	Operating Leases			Operating Leases
	As of January 31, 2015, we lease the following facilities under non-cancelable operating lease agreements:			As of April 30, 2014, we lease the following facilities under non-cancelable operating lease agreements:
		⋅	One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease expires in November 2016. The Company recognized $64 and $53 of rental costs relative to this lease for the nine months ended January 31, 2015 and 2014, respectively.	·          One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease expires in November 2016. The Company recognized $75,000 and $69,000 of rental costs relative to this lease for fiscal 2014 and 2013, respectively.
		⋅	855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of laboratories and office space where the Company conducts operations related to its primary service offerings.  This lease expires June 2016.  The Company recognized $65 and $64 of rental costs relative to this lease for nine months ended January 31, 2015 and 2014, respectively.	·          855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of laboratories and office space where the Company conducts operations related to its primary service offerings.  This lease expired in June 2014. The Company is currently in the process of renewing the lease. The Company recognized $85,000 and $90,000 of rental costs relative to this lease for fiscal 2014 and 2013, respectively.
		⋅	17 Hatidhar Street, Ra’anana, Israel, which served as office headquarters for Champions Oncology, Israel. This lease expired in July 2013 and was not renewed. The Company recognized nil and $6 of rental costs relative to this lease for the nine months ended January 31, 2015 and 2014, respectively.	·          17 Hatidhar Street, Ra’anana, Israel, which serves as office headquarters for Champions Oncology, Israel. The Company recognized $6,000 and $28,000 of rental costs relative to this lease for fiscal 2014 and 2013, respectively. Following the expiration of this lease, the Company utilizes office space on a limited basis from one of its stockholders. The fair value of rental costs associated with the new office space is immaterial.
		⋅	57 Mohamed Sultan Road, Singapore, which serves as office headquarters for Champions Oncology, Singapore. The lease expired in January 2015. The Company has not renewed this lease. We incurred $4 of rental expense for both the nine months ended January 31, 2015 and 2014, respectively.	·          57 Mohamed Sultan Road, Singapore, which serves as office headquarters for Champions Oncology, Singapore. The lease was renewed for one year and expires in January 2015. We incurred $5,000 and $2,000 of rental expense relative to this lease for fiscal 2014 and 2013, respectively
		⋅	450 East 29th Street, New York, New York, 10016, which is a laboratory at which we implant tumors. We incurred $35 of rental expense for the nine months ended January 31, 2015. The lease began in March 2014. The lease expires in September 2015 and can be renewed by the Company for subsequent one year terms.	·          450 East 29th Street, New York, New York, 10016, which is a laboratory at which we implant tumors.  We incurred no material costs relative to this lease in 2014 as the lease began in March 2014. The lease expires in September 2014 and can be renewed by the Company for subsequent one year terms.
	Legal Matters			Future minimum lease payments due each fiscal year are as follows (in thousands):
	The Company is not currently party to any legal matters to its knowledge. The Company is not aware of any other matters that would have a material impact on the Company’s financial position or results of operations.			2015	$	102,826
				2016		85,185
	Registration Payment Arrangements			2017		49,691
	The Company has entered into an Amended and Restated Registration Rights Agreement in connection with the April 2011 Private Placement and January 2013 Private Placement and is discussed more fully in Note 4. This Amended and Restated Registration Rights Agreement contains provisions that may call for the Company to pay penalties in certain circumstances. This registration payment arrangement primarily relates to the Company’s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period. The Company does not believe it is probable that penalty payments will be made for the Amended and Restated Registration Rights Agreement discussed in Note 4 and, accordingly, has not accrued for such potential penalties as of January 31, 2015 and April 30, 2014.			Total	$	237,702
				Legal Matters
				The Company is not currently party to any legal matters to its knowledge. The Company is not aware of any other matters that would have a material impact on the Company’s financial position or results of operations.
				Registration Payment Arrangements
				The Company has entered into an Amended and Restated Registration Rights Agreement in connection with the April 2011 Private Placement and January 2013 Private Placement and is discussed more fully in Note 7 below. This Amended and Restated Registration Rights Agreement contains provisions that may call for the Company to pay penalties in certain circumstances. This registration payment arrangement primarily relates to the Company’s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period. The Company does not believe it is probable that penalty payments will be made for the Amended and Restated Registration Rights Agreement discussed in Note 7 and, accordingly, has not accrued for such potential penalties as of April 30, 2014 and 2013.

Teva_Agreement

Teva Agreement	9 Months Ended	12 Months Ended
	Jan. 31, 2015	Apr. 30, 2014
Teva Agreement [Abstract]
Teva Agreement [Text Block]	Note 7. Teva Agreement	Note 3. Teva Agreement
	On July 30, 2013, the Company entered into an agreement with Teva Pharmaceutical Industries Ltd., pursuant to which the Company agreed to conduct TumorGraft studies on multiple proprietary chemical compounds provided by Teva to determine the activity or response of these compounds in potential clinical indications. Under the agreement, Teva agreed to pay an upfront payment and, under certain conditions, pay the Company various amounts upon achieving certain milestones, based on the performance of the compounds in preclinical testing and dependent upon testing the compound in clinical settings and obtaining FDA approval. In addition, Teva agreed to pay the Company royalties on any commercialized products developed under the agreement. This agreement terminated a prior collaborative agreement between Cephalon, Inc. a wholly-owned subsidiary of Teva, and the Company. Revenue recognized related to this agreement for the three months ended January 31, 2015 and 2014, was $94 and nil, respectively. Revenue recognized related to this agreement for the nine months ended January 31, 2015 and 2014, was $574 and $194, respectively.	On July 30, 2013, the Company entered into an agreement with Teva Pharmaceutical Industries Ltd., pursuant to which the Company agreed to conduct TumorGraft studies on multiple proprietary chemical compounds provided by Teva to determine the activity or response of these compounds in potential clinical indications. Under the agreement, Teva agreed to pay an upfront payment and, under certain conditions, pay the Company various amounts upon achieving certain milestones, based on the performance of the compounds in preclinical testing and dependent upon testing the compound in clinical settings and obtaining FDA approval. In addition, Teva agreed to pay the Company royalties on any commercialized products developed under the agreement. This agreement terminated a prior collaborative agreement between Cephalon, Inc. a wholly-owned subsidiary of Teva, and the Company. For the year ended April 30, 2014, revenue of $194,000 were recognized relating to this agreement.

Fair_Value

Fair Value	9 Months Ended
	Jan. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 8. Fair Value
	The carrying value of cash and cash equivalents, accounts receivable, prepaid expenses, deposits and other receivables, accounts payable, and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:
		⋅	Level one — Quoted market prices in active markets for identical assets or liabilities;
		⋅	Level two — Inputs other than level one inputs that are either directly or indirectly observable; and
		⋅	Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.
	Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company has one liability measured at fair value on a recurring basis, which are warrants that were issued in connection with private placements of the Company’s securities that are discussed more fully in Note 4. As of January 31, 2015 and April 30, 2014, these warrants had an estimated fair value of $0.6 million and $2.01 million, respectively, which was calculated by the Monte Carlo simulation valuation method using level three inputs. The Company has no assets that are measured at fair value on a recurring basis and there were no assets or liabilities measured at fair value on a non-recurring basis during the nine months ended January 31, 2015 and 2014.
	The following table presents information about our warrants liability, which was our only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of January 31, 2015 and April 30, 2014 (in thousands):
	Balance, May 1, 2014		$	-2,011
	Transfers to (from) Level 3			-
	Total (gains) losses included in earnings			1,401
	Purchases, issuances and settlements, net			-
	Balance, January 31, 2015		$	-610

Segment_Information

Segment Information	9 Months Ended									12 Months Ended
	Jan. 31, 2015									Apr. 30, 2014
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Note 9. Segment Information									Note 11. Business Segment Information
	The Company operates in two reportable segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2 of the Company’s annual financial statements for the year ended April 30, 2014, as filed on Form 10-K. The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by reportable segment (in thousands):									The Company operates in two segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2. The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by business segment (in thousands):
		Personalized		Translational						Year Ended April 30, 2014	Personalized		Translational		Unallocated		Consolidated
		Oncology		Oncology		Unallocated					Oncology		Oncology		Corporate
		Solutions		Solutions		Corporate					Solutions		Solutions		Overhead
	Three Months Ended January 31, 2015	(POS)		(TOS)		Overhead		Consolidated			(POS)		(TOS)
	Net revenue	$	453	$	1,376	$	-	$	1,829	Net revenue	$	2,264	$	9,286	$	-	$	11,550
	Direct cost of services		-672		-1,300		-		-1,972	Direct cost of services		-2,667		-3,496		-		-6,163
	Sales and marketing costs		-366		-613		-		-979	Sales and marketing costs		-1,723		-1,080		-		-2,803
	Other operating expenses		-		-1,028		-612		-1,640	Other operating expenses		-		-2,209		-3,828		-6,037
	Stock- based compensation expense (1)		-		-		-657		-657	Stock compensation expense (1)		-		-		-2,807		-2,807
	Segment profit (loss)	$	-585	$	-1,565	$	-1,269	$	-3,419	Segment profit (loss)	$	-2,126	$	2,501	$	-6,635	$	-6,260
		Personalized		Translational						Year Ended April 30, 2013	Personalized		Translational		Unallocated		Consolidated
		Oncology		Oncology		Unallocated					Oncology		Oncology		Corporate
		Solutions		Solutions		Corporate					Solutions		Solutions		Overhead
	Three Months Ended January 31, 2014	(POS)		(TOS)		Overhead		Consolidated			(POS)		(TOS)
	Net revenue	$	590	$	3,100	$	-	$	3,690	Net revenue	$	2,390	$	5,933	$	-	$	8,323
	Direct cost of services		-608		-1,007		-		-1,615	Direct cost of services		-2,604		-2,637		-		-5,241
	Sales and marketing costs		-405		-352		-		-757	Sales and marketing costs		-1,496		-938		-		-2,434
	Other operating expenses		-		-531		-1,254		-1,785	Other operating expenses		-134		-1,753		-2,606		-4,493
	Stock- based compensation expense (1)		-		-		-941		-941	Stock compensation expense (1)		-		-		-2,376		-2,376
	Segment profit (loss)	$	-423	$	1,210	$	-2,195	$	-1,408	Segment loss	$	-1,844	$	605	$	-4,982	$	-6,221
		Personalized		Translational						(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.
		Oncology		Oncology		Unallocated
		Solutions		Solutions		Corporate				All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.
	Nine Months Ended January 31, 2015	(POS)		(TOS)		Overhead		Consolidated
	Net revenue	$	1,245	$	4,377	$	-	$	5,622
	Direct cost of services		-2,171		-3,205		-		-5,376
	Sales and marketing costs		-1,243		-1,650		-		-2,893
	Other operating expenses		-		-3,490		-2,413		-5,903
	Stock- based compensation expense (1)		-		-		-2,284		-2,284
	Segment profit (loss)	$	-2,169	$	-3,968	$	-4,697	$	-10,834
		Personalized		Translational
		Oncology		Oncology		Unallocated
		Solutions		Solutions		Corporate
	Nine Months Ended January 31, 2014	(POS)		(TOS)		Overhead		Consolidated
	Net revenue	$	1,834	$	7,258	$	-	$	9,092
	Direct cost of services		-2,078		-2,572		-		-4,650
	Sales and marketing costs		-1,159		-812		-		-1,971
	Other operating expenses		-		-1,595		-2,790		-4,385
	Stock- based compensation expense (1)		-		-		-1,968		-1,968
	Segment profit (loss)	$	-1,403	$	2,279	$	-4,758	$	-3,882
	(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.
	All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.

Subsequent_Events

Subsequent Events	9 Months Ended
	Jan. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 10. Subsequent Events
	On February 28, 2015, the Company entered into amendments to the convertible promissory notes issued on December 1, 2014. The amendments extended the maturity dates of the convertible promissory notes to April 1, 2015 (see Note 5).
	On March 13, 2015, the Company entered into a 2015 Securities Purchase Agreement (the "2015 Securities Purchase Agreement") with Battery Ventures IX, L.P. and Battery Investment Partners IX, LLC (collectively, "Battery"), New Enterprise Associates 14, Limited Partnership ("NEA"), Joel Ackerman, Chief Executive Officer and a director of the Company ("Ackerman"), Dr. Ronnie Morris, President and a director of the Company ("Morris"), Daniel Mendelson, a director of the Company ("Mendelson") and certain other investors (collectively with Battery, NEA, Ackerman, Morris and Mendelson, the "Investors"), for the sale to the Investors of units, each unit consisting of one share of the Company's Common Stock, par value $0.001 per share (the "Common Stock"), and a warrant to buy 0.55 shares of Common Stock at $0.48 per share (the "Warrants"), at a purchase price of $0.40 per unit, for an aggregate of approximately $14,000,000. The Warrants expire five years after the closing date. As part of the $14 million transaction, Ackerman and Morris converted convertible promissory notes dated December 1, 2014 in the principal amounts of $1 million each, plus accrued interest, into the units at a 5% discount, pursuant to the terms of the convertible promissory notes.
	The Investors have the right to require the Company to repurchase the purchased shares (the "Put Option") for cash for $0.40 per share upon a change of control or sale or exclusive license of substantially all of the Company's assets only if approved by the Company's board of directors. The Put Option will terminate upon the achievement of certain financial and other milestones.
	The Investors have certain participation rights with respect to future financings of the Company, and have certain voting rights with respect to certain specified Company corporate actions, including the liquidation or dissolution of the Company; certain share repurchases by the Company; and mergers and consolidations by the Company below a stated sale price threshold. The Company covenanted to register the resale of the shares of Common Stock to be issued to the Investors and the shares of Common Stock issuable upon exercise of the Warrants pursuant to a 2015 Amended and Restated Registration Rights Agreement, to pay certain liquidated damages if the Company fails to file such registration statement by a certain deadline, and to have it declared effective by a certain deadline or keep it effective for a certain period of time.
	The issuance of the shares of Common Stock resulted in the Company issuing an additional  2,264,450 shares of Common Stock to investors who purchased shares of Common Stock pursuant to a Securities Purchase Agreement dated as of March 24, 2011 (the "2011 Securities Purchase Agreement") due to contractual anti-dilution provisions in that 2011 Securities Purchase Agreement. The Company also amended and restated the 2011 Securities Purchase Agreement to eliminate these anti-dilution provisions going forward, and conform aspects of the put option in that 2011 Securities Purchase Agreement to terms of the Put Option in the 2015 Securities Purchase Agreement. The Company also issued an additional 1,583,335 warrants to its investors under the 2011 Warrant Agreements under the Securities Purchase Agreement and had its investors agree on certain amendments of the warrants to eliminate the anti-dilution rights for future transactions, by extending the term of the warrants  by one year, and revising the exercise price to $0.40.
	The Company and its investors have  amended and restated its Securities Purchase Agreement dated January 28, 2013 (the "2013 Securities Purchase Agreement") to conform aspects of the put option in that 2013 Securities Purchase Agreement to the Put Option in the 2015 Securities Purchase Agreement. The Company issued an additional 1,209,001 warrants to investors under the 2013 Warrant Agreements under the Securities Purchase Agreement and had its investors agree on certain amendments of these warrants issued in connection with the 2013 Securities Purchase Agreement to eliminate the antidilution rights for future transactions, by extending the term of the warrant  by one year, revising the exercise price to $0.40.

Significant_Customers

Significant Customers	12 Months Ended
	Apr. 30, 2014
Significant Customer [Abstract]
Significant Customer [Text Block]	Note 4. Significant Customers
	For the year ended April 30, 2014, three of our customers accounted for more than 10.0% of our total revenue in the amount of $1.6 million, $1.5 million and $1.5 million. The revenue from these customers is captured in the TOS revenue line item within the income statement.

Licensing_Agreements

Licensing Agreements	12 Months Ended
	Apr. 30, 2014
Licensing Agreements [Abstract]
Licensing Agreements Disclosure [Text Block]	Note 6. Licensing Agreements
	In February 2010, the Company entered into an exclusive option agreement with a Canadian company. The option agreement granted the Company the exclusive right to review Irinophore C, a nanoparticle drug compound, for the treatment of various forms of cancer, including melanoma, prostate, breast, and lung cancer. On June 26th, 2014 the Company terminated its exclusive option agreement.

Redeemable_Common_Stock_and_St

Redeemable Common Stock and Stock Purchase Warrants	12 Months Ended
	Apr. 30, 2014
Redeemable Common Stock And Stock Purchase Warrant [Abstract]
Redeemable Common Stock And Stock Purchase Warrant [Text Block]	Note 8. Redeemable Common Stock and Stock Purchase Warrants
	On January 28, 2013, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 18,600,000 shares of the Company’s Common Stock at a purchase price of $0.50 per share, for aggregate proceeds of $9.3 million (net proceeds of $9.1 million due to issuance costs), $0.5 million of which was sold to officers and directors of the Company. This private placement transaction closed on January 28, 2013 (the “January 2013 Private Placement”). As part of this transaction, the Company also issued warrants to purchase an aggregate 1,860,000 shares of Common Stock at an exercise price of $0.66 per share. These warrants expire five years after the closing date . The Company also entered into an Amended and Restated Registration Rights Agreement on January 28, 2013 that provided certain registration rights with respect to the shares of Common Stock issued and the shares of Common Stock issuable upon exercise of the warrants. Furthermore, certain investors will have the right to require the Company to redeem the purchased common shares held by all of the investors (the “January 2013 Private Placement Put Option”) for cash of $0.50 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets. The January 2013 Private Placement Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement for the January 2013 Private Placement. The January 2013 Private Placement investors also have certain participation rights with respect to future financings of the Company. The terms of the January 2013 Private Placement resulted in the issuance of an additional 1,064,658 common shares to the investors of the April 2011 Private Placement under the anti-dilution protections granted such investors, which are discussed below.
	On March 24, 2011, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 12,533,333 shares of the Company’s Common Stock at a purchase price of $0.75 per share, for aggregate proceeds of $9.4 million, $0.5 million of which was sold to officers and directors of the Company. This private placement transaction closed April 4, 2011 (the “April 2011 Private Placement”). As part of this transaction, the Company also issued warrants to purchase an aggregate 1,266,667 shares of Common Stock at an exercise price of $0.90 per share. These warrants expire five years after the closing date. The Securities Purchase Agreement governing the April 2011 Private Placement contains certain anti-dilution protections for the investors. The Amended and Restated Registration Rights Agreement referenced above provides certain registration rights with respect to the shares of Common Stock issued and the shares of Common Stock issuable upon exercise of the warrants. Furthermore, certain investors have the right to require the Company to redeem the purchased common shares held by all of the investors (the “April 2011 Private Placement Put Option”) for cash for $0.75 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets. The April 2011 Private Placement Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement for the April 2011 Private Placement.
	Due to the April 2011 Private Placement Put Option and the January 2013 Private Placement Put Option described above, the Company has accounted for the Common Stock for the April 2011 Private Placement and January 2013 Private Placement as temporary equity, which is reflected under the caption “redeemable common stock” on the accompanying consolidated balance sheets for 2013. The total amount allocated to the redeemable common stock was $8.8 million for the January 2013 Private Placement and $8.2 million for the April 2011 Private Placement. For the January 2013 Private Placement, this allocation is equal to the total proceeds of $9.3 million less the amount allocated to the warrants of $0.4 million and is also net of the direct and incremental costs associated with the January 2013 Private Placement of $0.2 million. For the April 2011 Private Placement, this allocation is equal to the total proceeds of $9.4 million, less the amount allocated to the warrants of $0.9 million and is also net of direct and incremental costs associated with the April 2011 Private Placement of $0.3 million.
	On January 29, 2014, the Company executed amendments to the 2011 Securities Purchase Agreement and to the 2013 Securities Purchase Agreement with certain of the parties thereto, in each case revising the definition of “Change of Control” as it appears on the Securities Purchase Agreements.
	On January 29, 2014, the Company also entered into an agreement with Joel Ackerman, its Chief Executive Officer and a Director, and Ronnie Morris, its President and a Director, both of whom bought securities from the Company pursuant to the Securities Purchase Agreements, that, if the Company’s Board of Directors votes on a transaction, event or approval that would constitute a Put Option Trigger Event (as defined in each of the Securities Purchase Agreements), each of Ackerman and Morris shall either (a) recuse themselves from voting as a member of the Board of Directors on such transaction, event or approval or (b) be entitled to vote but forego exercising or receiving the benefit of their Put Right (as defined in each of the Securities Purchase Agreements).
	Prior to the January 29, 2014 amendments the Put Option Trigger Event (as defined in each of the Securities Purchase Agreements) was outside of the Company’s control. Subsequent to the January 29, 2014 amendments the Put Option Trigger Event is within the Company’s control. This change resulted in the common stock related to the April 2011 Private Placement and the 2013 Private Placement to be reclassified from outside of permanent equity (reflected under the caption “redeemable common stock”) to inside permanent equity (reflected in the captions “common stock” and “additional paid-in capital”) for 2014.
	The warrants issued in connection with both the April 2011 Private Placement and January 2013 Private Placement contain certain exercise price reset provisions. Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its Common Stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the April 2011 Private Placement and January 2013 Private Placement). These exercise price reset provisions resulted in a downward adjustment to the exercise price of the warrants issued in the April 2011 Private Placement from $0.90 to $0.50.
	The Company has accounted for the warrants issued in connection with the April 2011 Private Placement and January 2013 Private Placement as a liability based on the exercise price reset provisions described above. This liability, which is recorded at fair value on the accompanying consolidated balance sheets, totaled $0.8 million at the time of the close of the January 2013 Private Placement Agreement. As of April 30, 2014 and 2013, the fair value of these warrants was $2.01 million and $1.05 million, respectively. The change in fair value of these warrants has been, and will be, recognized as other income (expense) on the Company’s consolidated statements of operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. Assumptions used to calculate the fair value of these warrants were as follows:
		Year Ended April 30,
		2014	2013
	Expected term in years	1.9 - 3.7	2.9 - 4.7
	Risk-free interest rates	0.4% - 1.17%	0.30%
	Volatility	95% - 113%	95% - 98%
	Dividend yield	0%	0%
	The Company estimated the volatility based upon the applicable look-back periods or historical volatility observed for the Company. For the Risk-free rate the Company used the yield on a T-bill with maturity closest to the expected time to the warrant expiration.
	In addition to the assumptions above, the Company also takes into consideration whether or not the Company would participate in another round of financing and if that financing is registered or not and what that stock price would be for the financing at that time.
	The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants.
	The Company has granted demand registration rights in connection with the investment in common shares and the common shares underlying the warrants for both the April 2011 Private Placement and January 2013 Private Placement. These rights include the requirement of the Company to file certain registration statements within a specified time period and to have these registration statements declared effective within a specified time period. If the Company is not able to comply with these registration requirements, the Company will be required to pay cash penalties equal to 1.0% of the aggregate Purchase Price paid by the investors for each 30-day period in which a Registration Default, as defined in the Securities Purchase Agreement, exists. These penalties are subject to a 10% limit of the aggregate Purchase Price paid by the investors. The Company may become subject to these penalty provisions if it fails to have a registration statement for the common shares declared effective, or to maintain the effectiveness of such registration statement. The total amount of potential penalties under this registration payment arrangement ranges from $50,000 to $130,000 for each 30-day period in which a registration default exists; however, as of April 30, 2014 and through the date of this filing, the Company does not believe these penalties to be probable and accordingly, has not established an accrual for such registration payment arrangements.

Provision_for_Income_Taxes

Provision for Income Taxes	12 Months Ended
	Apr. 30, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 9. Provision for Income Taxes
	The components of the provision (benefit) for income taxes are as follows (in thousands):
		Year Ended April 30, 2014
		Federal			State			Foreign		Total
	Current	$	-		$	5		$	12	$	17
	Deferred		-2,015			-148			-		-2,163
	Change in valuation allowance		2,015			148			-		2,163
	Total	$	-		$	5		$	12	$	17
		Year Ended April 30, 2013
		Federal			State			Foreign		Total
	Current	$	-		$	2		$	8	$	10
	Deferred		-2,258			-196			-		-2,454
	Change in valuation allowance		2,258			196			-		2,454
	Total	$	-		$	2		$	8	$	10
	A reconciliation between the Company’s effective tax rate and the United States statutory tax rate for the years ended April 30, 2014 and 2013 is as follows:
		Year Ended April 30,
		2014			2013
	Federal income tax at statutory rate		34	%		34	%
	State income tax, net of federal benefit		2.1			2.6
	Permanent differences		-5.6			-0.5
	Other		-2.1			1.6
	Change in valuation allowance		-27.2			-39.6
	Changes in tax rates		-1.4			1.7
	Income tax expense		-0.2	%		-0.2	%
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of the Company’s deferred tax assets and liabilities as of April 30, 2014 and 2013 consist of the following (in thousands):
	Accrued liabilities	$	38		$	89
	Depreciation and amortization		9			51
	State taxes		1			7
	Stock-based compensation expense		4,511			3,582
	Capitalized research and development costs		556			688
	Foreign net operating loss carry-forward		244			386
	Net operating loss carry-forward		5,608			4,144
	Total deferred tax assets		10,968			8,948
	Less: Valuation allowance		-10,968			-8,948
	Net deferred tax asset	$	-		$	-
	Management has evaluated the available evidence about future tax planning strategies, taxable income and other possible sources of realization of deferred tax assets and has established a full valuation allowance against its net deferred tax assets as of April, 30, 2014 and 2013.  For the years ended April 30, 2014 and 2013, the Company recorded a valuation allowance of $10,968,000 and $8,948,000, respectively.  The increase in valuation allowance from fiscal year 2013 to 2014 is due to deferred tax assets generated relative to stock compensation and net operating loss carryforwards.  The Company has established a valuation allowance against its deferred tax assets as it is currently more-likely-than-not that all or a portion of a deferred tax asset will not be realized.  The valuation allowance reduces deferred tax assets to an amount that management believes will more likely than not be realized.  Changes in valuation allowances from period to period are included in the tax provision in the period of change.  In determining whether a valuation allowance is required, the Company takes into account all evidence with regard to the utilization of a deferred tax asset including past earnings history, expected future earnings, the character and jurisdiction of such earnings, unsettled circumstances that, if unfavorably resolved, would adversely affect utilization of a deferred tax asset, carryback and carryforward periods, and tax strategies that could potentially enhance the likelihood of realization of a deferred tax asset.
	As of April 30, 2014 and 2013, the Company’s estimated U.S. net operating loss carry-forwards were approximately $15,426,000 and $11,216,000, respectively.  As of April 30, 2014 and 2013, the Company’s foreign net operating loss carry-forward was approximately $1,034,000 and $1,744,000, respectively.  The Company’s federal and state net operating losses begin expiring in 2029.
	The Company files income tax returns in various jurisdictions with varying statues of limitations.  As of April 30, 2014, the earliest tax year still subject to examination for state purposes is fiscal 2011.  The Company’s tax years for periods ending April 30, 2000 and forward are subject to examination by the United States and certain states due to the carry-forward of unutilized net operating losses.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Apr. 30, 2014
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
	The Company’s foreign subsidiaries, functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with a maturity of three months or less at the time of purchase, to be cash equivalents. At various times, the Company has amounts on deposit at financial institutions in excess of federally insured limits.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value
	The carrying value of cash and cash equivalents, accounts receivable, prepaid expenses, deposits and other receivables, accounts payable, and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:
	·             Level one — Quoted market prices in active markets for identical assets or liabilities;
	·            Level two — Inputs other than level one inputs that are either directly or indirectly observable; and
	·            Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.
	Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company has one liability measured at fair value on a recurring basis, which are warrants that were issued in connection with private placements of the Company’s securities that are discussed more fully in Note 6. As of April 30, 2014 and 2013, these warrants had an estimated fair value of $2,011,000 and $1,046,000, respectively, which was calculated by the Monte Carlo simulation valuation method using level three inputs. The Company has no assets that are measured at fair value on a recurring basis and there were no assets or liabilities measured at fair value on a non-recurring basis during the years ended April 30, 2014 and 2013.
	The following table presents information about our warrant liability, which was our only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of April 30 (dollars in thousands):
			2014		2013
	Balance beginning of year		$	-1,046	$	-555
	Transfers to (from) Level 3			-		-
	Total gains (losses) included in earnings			-965		-74
	Issuances			-		-417
	Balance end of year		$	-2,011	$	-1,046
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts Receivable
	Accounts receivable represent amounts due under agreements with pharmaceutical and biotechnology companies for TOS and amounts due under agreements with patients for POS. At each reporting period, the Company evaluates open accounts receivable for collectability and records an allowance for potentially uncollectible accounts. As of April 30, 2014 and 2013, the allowance for these accounts was $2,000 and $19,000, respectively. Accounts receivable is also comprised of certain unbilled accounts receivable for services completed under TOS that have not been billed as of the balance sheet date. As of April 30, 2014 and 2013, the Company had unbilled receivables of $884,000 and $200,000, respectively.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash
	As of April 30, 2014 and 2013, the Company has restricted cash of $165,000 and $192,000, respectively, which is classified as a noncurrent asset on the consolidated balance sheets. This restricted cash serves as collateral for corporate credit cards to provide financial assurance that the Company will fulfill its obligations. The cash is held in custody by the issuing bank, is restricted as to withdrawal or use, and is currently invested in an interest-bearing Certificate of Deposit (“CD”). Though the CD matures in the second quarter of fiscal 2015, the cash will be reinvested into another CD to continue use of the corporate cards. The Company accounts for this CD as a non-current asset supporting operations of the business.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment
	Property and equipment is recorded at cost and primarily consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following (in thousands):
			April 30,
			2014		2013
	Furniture and fixtures		$	69	$	59
	Computer equipment and software			655		549
	Laboratory equipment			296		179
	Leasehold improvements			2		2
	Total property and equipment			1,022		789
	Less: Accumulated depreciation			-588		-375
	Property and equipment, net		$	434	$	414
	Depreciation expense was $213,000 and $203,000 for the years ended April 30, 2014 and 2013, respectively.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets
	Impairment losses are to be recognized when the carrying amount of a long-lived asset is not recoverable or exceeds its fair value.  The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that a carrying value may not be recoverable.  The Company uses estimates of future cash flows over the remaining useful life of a long- lived asset or asset group to determine the recoverability of the asset.  These estimates only include the net cash flows directly associated with, and that are expected to arise as a direct result of, the use and eventual disposition of the asset or asset group.  The Company has not recognized any impairment losses for the Company’s long-lived assets for the years ending April 30, 2014 and 2013.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill
	Goodwill represents the excess of the cost over the fair market value of the net assets acquired including identifiable assets. Goodwill is tested annually, or more frequently if circumstances indicate potential impairment, by comparing its fair value to its carrying amount. The determination of whether or not goodwill is impaired involves significant judgment. Although the Company believes its goodwill is not impaired, changes in strategy or market conditions could significantly impact the judgments and may require future adjustments to the carrying value of goodwill. The Company uses a two-step process to test for goodwill impairment. The first step is to screen for potential impairment, while the second step measures the amount of the impairment, if any. The first step of the goodwill impairment test compares the fair value of each reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired. If the carrying value of the reporting unit’s net assets, including goodwill, exceeds the fair value of the reporting unit, then the Company determines the implied fair value of goodwill. If the carrying value of goodwill exceeds its implied fair value, then an impairment of goodwill has occurred and an impairment loss would be recognized for the difference between the carrying amount and the implied fair value of goodwill as a component of operating income. The implied fair value of goodwill is calculated by subtracting the fair value of tangible and intangible assets associated with the reporting unit from the fair value of the unit. The Company tests for goodwill impairment at the operating segment level.
	The Company has not recognized any impairment losses for the Company’s goodwill for the years ending April 30, 2014 and 2013.
Revenue Recognition, Deferred Revenue [Policy Text Block]	Deferred Revenue
	Deferred revenue represents payments received in advance for products to be delivered.  When products are delivered, deferred revenue is then recognized as earned.
Warrant Liability [Policy Text Block]	Warrant Liability
	Warrant liability represents the fair value of warrants issued in connection with private placements of the Company’s common stock, which are described more fully in Note 7. These warrants are presented as liabilities based on the certain exercise price reset provisions.  The liability, which is recorded at fair value on the accompanying consolidated balance sheets, is calculated by the Monte Carlo simulation valuation method.  The change in fair value of these warrants is recognized as other income or expense in the consolidated statements of operations.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	The Company derives revenue from its POS and TOS businesses. Personalized oncology solutions assist physicians by providing information to help guide the development of personalized treatment plans for their patients using our core offerings, including testing oncology drugs and drug combinations on personalized TumorGrafts, and through other products. Translational oncology solutions offer a preclinical TumorGraft platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings. The Company recognizes revenue when the following four basic criteria are met: (i) a contract has been entered into with its customers; (ii) delivery has occurred or services rendered to its customers; (iii) the fee is fixed and determinable as noted in the contract; and (iv) collectability is reasonably assured. The Company utilizes a proportional performance revenue recognition model for its TOS business, under which it recognizes revenue as performance occurs, based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement, typically the delivery of reports to its customers documenting the results of testing protocols.
	When a POS or TOS arrangement involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. The Company performs this evaluation at the inception of an arrangement and as each item in the arrangement is delivered. Generally, the Company accounts for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) has standalone value to the customer, and (ii) if the Company has given the customer a general right of return relative to the delivered item(s) and the delivery or performance of the undelivered item(s) or service(s) is probable and substantially in the Company’s control. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or if there is no predominant deliverable upon delivery of the final element of the arrangement.
	During the third quarter of fiscal year 2014 we entered into a contract that may require the replacement of licensed tumors in the event that certain contractual terms have not been satisfied. Due to such requirements we have estimated an amount of licensed tumors that may need to be replaced, and we have deferred this revenue until all provisions of the agreement have been met. There was $258,000 of deferred revenue as of April 30, 2014 relating to our estimate of replacement of licensed tumors.
Cost Of Personalized Oncology Solutions [Policy Text Block]	Cost of Personalized Oncology Solutions
	Cost of POS consists of costs related to POS revenue earned from implantations, drug panels, tumor boards, and gene sequencing services, as well as indirect internal costs, such as salaries for personnel directly engaged in these products. Direct costs associated with implantation revenues are primarily related to mice purchases and maintenance and shipping of tumor tissue. Direct drug panel costs are primarily incurred from mice purchases and maintenance and drug purchases. Direct tumor board costs are primarily related to physicians’ honorariums and any tumor board participation costs such as travel, lodging and meals. Direct gene sequencing costs are primarily related to costs billed from the gene sequencing service provider. All costs are expensed as incurred.
Cost Of Translational Oncology Solutions [Policy Text Block]	Cost of Translational Oncology Solutions
	Cost of TOS consists of costs related to TOS revenue. Direct costs include mice purchases and maintenance costs for studies completed internally and charges from CROs for studies handled externally. Indirect costs include salaries for personnel directly engaged in providing TOS products. All costs of performing studies in-house are expensed as incurred.
Research and Development Expense, Policy [Policy Text Block]	Research and Development
	Research and development costs represent both costs incurred internally for research and development activities, including personnel costs and mice purchases and maintenance, as well as costs incurred externally to facilitate research activities, such as tumor tissue procurement and characterization expenses.  All research and development costs are expensed as incurred. .
Cost of Sales, Policy [Policy Text Block]	Sales and Marketing
	Selling and marketing expenses represent costs incurred to promote the Company’s products offered, including salaries, benefits and related costs of our sales and marketing personnel, and represent costs of advertising and other selling and marketing expenses. All sales and marketing costs, including advertising costs, are expensed as incurred.
Earnings Per Share, Policy [Policy Text Block]	Basic and Dilutive Loss Per Common Share
	Basic loss per share is calculated by dividing loss available to common shareholders by the weighted average number of common shares (including redeemable common stock) outstanding for the year.  Diluted loss per share is calculated based on the weighted average number of common shares (including redeemable common stock) outstanding for the year, plus the dilutive effect of common stock purchase warrants, stock options and restricted stock units using the treasury stock method.  Contingently issuable shares are included in the calculation of basic earnings per share when all contingencies surrounding the issuance of the shares are met and the shares are issued or issuable.  Contingently issuable shares are included in the calculation of dilutive earnings per share as of the beginning of the reporting period if, at the end of the reporting period, all contingencies surrounding the issuance of the shares are satisfied or would be satisfied if the end of the reporting period were the end of the contingency period.  Due to the net losses for the years ended April 30, 2014 and 2013, basic and diluted loss per share were the same, as the effect of potentially dilutive securities (as listed below) would have been anti-dilutive.
	The following table reflects the total potential share-based instruments outstanding at April 30, 2014 and 2013, that could have an effect on the future computation of dilution per common share:
			Year Ended April 30,
			2014		2013
	Stock options			23,351,037		13,890,205
	Warrants			3,276,667		3,276,667
	Restricted stock			-		50,000
	Total common stock equivalents			26,627,704		17,216,872
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-Based Payments
	The Company typically recognizes expense for share-based payments based on the fair value of awards on the date of grant. The Company uses the Black-Scholes option pricing model to estimate fair value. The Black-Scholes option valuation model was developed for use in estimating the fair value of short-traded options that have no vesting restrictions and are fully transferable. The option pricing model requires the Company to estimate certain key assumptions such as expected life, volatility, risk free interest rates and dividend yield to determine the fair value of share-based awards. These assumptions are based on historical information and management judgment. The risk-free interest rate used is based on the United States treasury security rate with a term consistent with the expected term of the award at the time of the grant. Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the Securities and Exchange Commission-approved “simplified method” noted under the provisions of Staff Accounting Bulletin No. 107 with the continued use of this method extended under the provisions of Staff Accounting Bulletin No. 110. During fiscal 2013, the Company changed its method used to calculate expected volatility from an index, which was based on the Company’s historic volatility and certain comparable guideline companies, to the use of only the Company’s historic volatility which had an immaterial effect on the financial statements. The Company does not anticipate paying a dividend, and therefore, no expected dividend yield was used.
	The Company expenses share-based payments over the period that the awards are expected to vest, net of estimated forfeitures. If actual forfeitures differ from management’s estimates, compensation expense is adjusted. The Company will report cash flows resulting from tax deductions in excess of the compensation cost recognized from those options (excess tax benefits) as financing cash flows, if they should arise.
Income Tax, Policy [Policy Text Block]	Income Taxes
	Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements.  In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is not likely or there is insufficient operating history, a valuation allowance is established.  The Company adjusts the valuation allowance in the period management determines it is more likely than not that net deferred tax assets will or will not be realized.  As of April 30, 2014 and 2013, the Company provided a valuation allowance for all net deferred tax assets, as recovery is not more likely than not based on an insufficient history of earnings.
	Tax positions are positions taken in a previously filed tax return or positions expected to be taken in a future tax return that are reflected in measuring current or deferred income tax assets and liabilities reported in the consolidated financial statements.  Tax positions include, but are not limited to, the following:
		·	An allocation or shift of income between taxing jurisdictions;
		·	The characterization of income or a decision to exclude reportable taxable income in a tax return; or
		·	A decision to classify a transaction, entity or other position in a tax return as tax exempt.
	The Company reflects tax benefits only if it is more likely than not that we will be able to sustain the tax position, based on its technical merits. If a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized. The Company has no unrecognized tax benefits as of April 30, 2014 and 2013.
	The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company’s balance sheets at April 30, 2013 and 2012, and has not recognized interest and/or penalties in the statement of operations for either period.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09 Revenue from Contracts with Customers (Topic 606). This guidance is intended to improve and converge with international standards the financial reporting requirements for revenue from contracts with customers. It will be effective for our first quarter of fiscal year 2018 and early adoption is not permitted. We have not yet determined the impact from adoption of this new accounting pronouncement on our financial statements.

Organization_Use_of_Estimates_1

Organization, Use of Estimates and Basis of Presentation (Tables)	9 Months Ended													12 Months Ended
	Jan. 31, 2015													Apr. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]		Three Months Ended						Nine Months Ended
		January 31,						January 31,
		2015			2014			2015			2014
	Basic loss per share computation
	Net loss attributable to common stockholders	$	(2,816,465	)	$	(574,207	)	$	(9,462,281	)	$	(5,133,684	)
	Weighted Average common shares - basic		66,893,364			66,867,114			66,890,929			66,860,792
	Basic net loss per share	$	(0.04	)	$	(0.01	)	$	(0.14	)	$	(0.08	)
	Diluted loss per share computation
	Net loss attributable to common stockholders	$	(2,816,465	)	$	(574,207	)	$	(9,462,281	)	$	(5,133,684	)
	Less: Gain on derivative warrant liability		620,687			845,774			1,401,314			-
	Loss available to common stockholders	$	(3,437,152	)	$	(1,419,981	)	$	(10,863,595	)	$	(5,133,684	)
	Weighted Average common shares		66,893,364			66,867,114			66,890,929			66,860,792
	Incremental shares from assumed exercise of warrants and stock options		352,213			-			352,213			-
	Adjusted weighted average share - diluted		67,245,577			66,867,114			67,243,142			66,860,792
	Diluted net loss per share	$	(0.05	)	$	(0.02	)	$	(0.16	)	$	(0.08	)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table reflects the total potential share-based instruments outstanding at January 31, 2015 and 2014 that could have an effect on the future computation of dilution per common share:													The following table reflects the total potential share-based instruments outstanding at April 30, 2014 and 2013, that could have an effect on the future computation of dilution per common share:
		January 31,													Year Ended April 30,
		2015			2014										2014		2013
	Stock options		23,990,008			22,633,955								Stock options		23,351,037		13,890,205
	Warrants		3,126,667			3,276,667								Warrants		3,276,667		3,276,667
														Restricted stock		-		50,000
	Total common stock equivalents		27,116,675			25,910,622
														Total common stock equivalents		26,627,704		17,216,872

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended					12 Months Ended
	Jan. 31, 2015					Apr. 30, 2014
Accounting Policies [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table presents information about our warrants liability, which was our only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of January 31, 2015 and April 30, 2014 (in thousands):					The following table presents information about our warrant liability, which was our only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of April 30 (dollars in thousands):
	Balance, May 1, 2014	$	-2,011				2014		2013
	Transfers to (from) Level 3		-
	Total (gains) losses included in earnings		1,401			Balance beginning of year	$	-1,046	$	-555
	Purchases, issuances and settlements, net		-			Transfers to (from) Level 3		-		-
						Total gains (losses) included in earnings		-965		-74
	Balance, January 31, 2015	$	-610			Issuances		-		-417
						Balance end of year	$	-2,011	$	-1,046
Public Utility Property, Plant, and Equipment [Table Text Block]						Property and equipment is recorded at cost and primarily consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following (in thousands):
							April 30,
							2014		2013
						Furniture and fixtures	$	69	$	59
						Computer equipment and software		655		549
						Laboratory equipment		296		179
						Leasehold improvements		2		2
						Total property and equipment		1,022		789
						Less: Accumulated depreciation		-588		-375
						Property and equipment, net	$	434	$	414
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table reflects the total potential share-based instruments outstanding at January 31, 2015 and 2014 that could have an effect on the future computation of dilution per common share:					The following table reflects the total potential share-based instruments outstanding at April 30, 2014 and 2013, that could have an effect on the future computation of dilution per common share:
		January 31,					Year Ended April 30,
		2015		2014			2014		2013
	Stock options		23,990,008		22,633,955	Stock options		23,351,037		13,890,205
	Warrants		3,126,667		3,276,667	Warrants		3,276,667		3,276,667
						Restricted stock		-		50,000
	Total common stock equivalents		27,116,675		25,910,622
						Total common stock equivalents		26,627,704		17,216,872

Provision_for_Income_Taxes_Tab

Provision for Income Taxes (Tables)	12 Months Ended
	Apr. 30, 2014
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components of the provision (benefit) for income taxes are as follows (in thousands):
		Year Ended April 30, 2014
		Federal			State			Foreign		Total
	Current	$	-		$	5		$	12	$	17
	Deferred		-2,015			-148			-		-2,163
	Change in valuation allowance		2,015			148			-		2,163
	Total	$	-		$	5		$	12	$	17
		Year Ended April 30, 2013
		Federal			State			Foreign		Total
	Current	$	-		$	2		$	8	$	10
	Deferred		-2,258			-196			-		-2,454
	Change in valuation allowance		2,258			196			-		2,454
	Total	$	-		$	2		$	8	$	10
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	A reconciliation between the Company’s effective tax rate and the United States statutory tax rate for the years ended April 30, 2014 and 2013 is as follows:
		Year Ended April 30,
		2014			2013
	Federal income tax at statutory rate		34	%		34	%
	State income tax, net of federal benefit		2.1			2.6
	Permanent differences		-5.6			-0.5
	Other		-2.1			1.6
	Change in valuation allowance		-27.2			-39.6
	Changes in tax rates		-1.4			1.7
	Income tax expense		-0.2	%		-0.2	%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of the Company’s deferred tax assets and liabilities as of April 30, 2014 and 2013 consist of the following (in thousands):
	Accrued liabilities	$	38		$	89
	Depreciation and amortization		9			51
	State taxes		1			7
	Stock-based compensation expense		4,511			3,582
	Capitalized research and development costs		556			688
	Foreign net operating loss carry-forward		244			386
	Net operating loss carry-forward		5,608			4,144
	Total deferred tax assets		10,968			8,948
	Less: Valuation allowance		-10,968			-8,948
	Net deferred tax asset	$	-		$	-

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended						12 Months Ended
	Jan. 31, 2015						Apr. 30, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment is recorded at cost and consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following (in thousands):
		January 31,			April 30,
		2015			2014
		(unaudited)
	Furniture and fixtures	$	70		$	69
	Computer equipment and software		694			655
	Laboratory equipment		457			296
	Leasehold improvements		2			2
	Total property and equipment		1,223			1,022
	Less: Accumulated depreciation		-754			-588
	Property and equipment, net	$	469		$	434
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	The following is a schedule by years of future minimum lease payments under this capital lease together with the present value of the net minimum lease payments as of January 31, 2015:						Future minimum lease payments due each fiscal year are as follows (in thousands):
	For the Years Ended April 30,	2015		$	6		2015	$	102,826
		2016			23		2016		85,185
		2017			24		2017		49,691
		2018			25
		2019			26		Total	$	237,702
		2020			16
	Total minimum lease payments			$	120
	Less: current maturity				-22
	Long-term maturity				98

ShareBased_Payments_Tables

Share-Based Payments (Tables)	9 Months Ended														12 Months Ended
	Jan. 31, 2015														Apr. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	As of January 31, 2015, $158 of stock compensation is included within accrued liabilities line item on the balance sheet. Stock-based compensation expense was recognized as follows (in thousands):														Stock-based compensation costs were recorded as follows (in thousands):
		Three Months Ended						Nine Months Ended								Year Ended April 30,
		January 31,						January 31,								2014		2013
		2015			2014			2015			2014
															General and administrative	$	2,298	$	1,984
	General and administrative	$	474		$	866		$	1,530		$	1,686			Sales and marketing		352		263
	Sales and marketing		114			63			447			189			Research and development		36		37
	Research and development		65			4			267			19			TOS cost of sales		56		20
	TOS cost of sales		2			2			20			12			POS cost of sales		65		72
	POS cost of sales		2			6			20			62
															Total stock-based compensation expense	$	2,807	$	2,376
	Total stock-based compensation expense	$	657		$	941		$	2,284		$	1,968
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2015 and 2014 were as follows (in thousands):														Black-Scholes assumptions used to calculate the fair value of options granted during the years ended April 30, 2014 and 2013 were as follows:
		Three Months Ended				Nine Months Ended										Year Ended April 30,
		January 31,				January 31,										2014		2013
		2015		2014		2015		2014
															Expected term in years		3.0 - 6.0		3.0 - 6.0
	Expected term in years	-		6-May		6-Mar		6-May							Risk-free interest rates		0.7% - 2.4%		0.7% - 1.3%
	Risk-free interest rates	-		1.4% - 2.1%		0.79% - 1.94%		0.8% - 2.4%							Volatility		84% - 102%		88% - 104%
	Volatility	-		97% - 102%		85.8% - 102.1%		97% - 102%							Dividend yield		0%		0%
	Dividend yield	-		0%		0%		0%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The Company’s stock options activity for the nine months ended January 31, 2015 is as follows:														The Company’s stock options activity and related information as of and for the years ended April 30, 2014 and 2013 is as follows (dollars in thousands):
											Weighted													Weighted
								Weighted			Average											Weighted		Average
				Directors				Average			Remaining		Aggregate					Directors				Average		Remaining		Aggregate
		Non-		and				Exercise			Contractual		Intrinsic			Non-		and				Exercise		Contractual		Intrinsic
		Employees		Employees		Total		Price			Life (Years)		Value			Employees		Employees		Total		Price		Life (Years)		Value
	Outstanding, May 1, 2014	765,000		22,586,037		23,351,037		$	1.01		7.5		$	985	Outstanding, May 1, 2013		765,000		13,125,205		13,890,205	$	0.85		7	$	89,000
	Granted	80,000		1,013,175		1,093,175			0.72		5.9			-	Granted		-		9,793,332		9,793,332		1.23
	Exercised	-		-3,750		-3,750			0.49						Exercised		-		-33,750		-33,750		0.63
	Forfeited	-		-101,250		-101,250			0.96						Canceled		-		-		-		-
	Expired	-150,000		-199,204		-349,204			1.04						Forfeited		-		-72,500		-72,500		0.82
															Expired		-		-226,250		-226,250		0.73
	Outstanding, January 31, 2015	695,000		23,295,008		23,990,008			1		6.6			63
															Outstanding, April 30, 2014		765,000		22,586,037		23,351,037		1.01		7.5	$	985,000
	Vested and expected to vest as of January 31, 2015	695,000		23,295,008		23,990,008			1		6.6			63
															Vested and expected to vest as of April 30, 2014		765,000		22,586,037		23,351,037				7.5	$	985,000
	Exercisable as of January 31, 2015	487,500		16,544,466		17,031,966			0.91		5.8			62
															Exercisable as of April 30, 2014		522,292		13,042,285		13,564,577		0.85		6.1	$	927,000
																								Weighted
																						Weighted		Average
																		Directors				Average		Remaining		Aggregate
																Non-		and				Exercise		Contractual		Intrinsic
																Employees		Employees		Total		Price		Life (Years)		Value
															Outstanding, May 1, 2012		1,410,000		13,456,038		14,866,038	$	0.88		7.6	$	-
															Granted		130,000		611,250		741,250		0.41
															Exercised		-		-		-		-
															Canceled		-		-25,000		-25,000		0.62
															Forfeited		-		-551,250		-551,250		0.72
															Expired		-775,000		-365,833		-1,140,833		0.95
															Outstanding, April 30, 2013		765,000		13,125,205		13,890,205		0.85		7	$	89,000
															Vested and expected to vest as of April 30, 2013		765,000		13,125,205		13,890,205				7	$	89,000
															Exercisable as of April 30, 2013		458,334		10,886,120		11,344,454		0.86		6.9	$	54,000
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]															A summary of the activity related to restricted stock grants for the years ended April 30, 2014 and 2013 is as follows (dollars in thousands):
																2014				2013
																		Weighted				Weighted
																		Average				Average
																		Grant Date				Grant Date
																Total		Fair Value		Total		Fair Value
																Shares		Per Share		Shares		Per Share
															Nonvested, beginning of period		50,000	$	0.3		25,000	$	0.75
															Granted		-		-		100,000		0.3
															Vested		-50,000		0.3		-75,000		0.45
															Forfeited		-		-		-
															Expired		-		-		-
															Nonvested, end of period		-		-		50,000		0.3
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Assumptions used to calculate the fair value of these warrants were as follows:
		January 31,		April 30,
		2015		2014
	Expected term in years	1.2 - 3.0		1.9 - 3.7
	Risk-free interest rates	0.6% - 1.05%		0.4% - 1.17%
	Volatility	73% - 100%		95% - 113%
	Dividend yield	0%		0%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Activity related to these warrants, which expire at various dates through April 2016, is summarized as follows (dollars in thousands):														Activity related to these warrants, which expire at various dates through April 2016, is summarized as follows (dollars in thousands):
							Weighted													Weighted
				Weighted			Average											Weighted		Average
		Number		Average			Remaining		Aggregate							Number		Average		Remaining		Aggregate
		of		Exercise			Contractual		Intrinsic							of		Exercise		Contractual		Intrinsic
		Shares		Price			Life (Years)		Value							Shares		Price		Life (Years)		Value
	Outstanding, May 1, 2014	3,276,667		$	0.61		2.9		$	984					Outstanding, May 1, 2013		3,276,667	$	0.61		3.9	$	-
	Granted	-			-		-			-					Granted		-		-		-
	Exercised	-			-		-			-					Exercised		-		-
	Expired	-150,000			-		-			-					Forfeited		-		-
															Expired		-		-
	Outstanding, January 31, 2015	3,126,667		$	0.6		2.3		$	-
															Outstanding, April 30, 2014		3,276,667	$	0.61		2.9	$	984,333
																				Weighted
																		Weighted		Average
																Number		Average		Remaining		Aggregate
																of		Exercise		Contractual		Intrinsic
																Shares		Price		Life (Years)		Value
															Outstanding, May 1, 2012		1,416,667	$	0.5		3.8	$	-
															Granted		1,860,000		0.66		4.8
															Exercised		-		-
															Forfeited		-		-
															Expired		-		-
															Outstanding, April 30, 2013		3,276,667	$	0.61		3.9	$	-

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended				12 Months Ended
	Jan. 31, 2015				Apr. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	The following is a schedule by years of future minimum lease payments under this capital lease together with the present value of the net minimum lease payments as of January 31, 2015:				Future minimum lease payments due each fiscal year are as follows (in thousands):
	For the Years Ended April 30,	2015	$	6	2015	$	102,826
		2016		23	2016		85,185
		2017		24	2017		49,691
		2018		25
		2019		26	Total	$	237,702
		2020		16
	Total minimum lease payments		$	120
	Less: current maturity			-22
	Long-term maturity			98

Fair_Value_Tables

Fair Value (Tables)	9 Months Ended			12 Months Ended
	Jan. 31, 2015			Apr. 30, 2014
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table presents information about our warrants liability, which was our only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of January 31, 2015 and April 30, 2014 (in thousands):			The following table presents information about our warrant liability, which was our only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of April 30 (dollars in thousands):
	Balance, May 1, 2014	$	-2,011		2014		2013
	Transfers to (from) Level 3		-
	Total (gains) losses included in earnings		1,401	Balance beginning of year	$	-1,046	$	-555
	Purchases, issuances and settlements, net		-	Transfers to (from) Level 3		-		-
				Total gains (losses) included in earnings		-965		-74
	Balance, January 31, 2015	$	-610	Issuances		-		-417
				Balance end of year	$	-2,011	$	-1,046

Segment_Information_Tables

Segment Information (Tables)	9 Months Ended									12 Months Ended
	Jan. 31, 2015									Apr. 30, 2014
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The following tables summarize, for the periods indicated, operating results by reportable segment (in thousands):									The following tables summarize, for the periods indicated, operating results by business segment (in thousands):
		Personalized		Translational						Year Ended April 30, 2014	Personalized		Translational		Unallocated		Consolidated
		Oncology		Oncology		Unallocated					Oncology		Oncology		Corporate
		Solutions		Solutions		Corporate					Solutions		Solutions		Overhead
	Three Months Ended January 31, 2015	(POS)		(TOS)		Overhead		Consolidated			(POS)		(TOS)
	Net revenue	$	453	$	1,376	$	-	$	1,829	Net revenue	$	2,264	$	9,286	$	-	$	11,550
	Direct cost of services		-672		-1,300		-		-1,972	Direct cost of services		-2,667		-3,496		-		-6,163
	Sales and marketing costs		-366		-613		-		-979	Sales and marketing costs		-1,723		-1,080		-		-2,803
	Other operating expenses		-		-1,028		-612		-1,640	Other operating expenses		-		-2,209		-3,828		-6,037
	Stock- based compensation expense (1)		-		-		-657		-657	Stock compensation expense (1)		-		-		-2,807		-2,807
	Segment profit (loss)	$	-585	$	-1,565	$	-1,269	$	-3,419	Segment profit (loss)	$	-2,126	$	2,501	$	-6,635	$	-6,260
		Personalized		Translational						Year Ended April 30, 2013	Personalized		Translational		Unallocated		Consolidated
		Oncology		Oncology		Unallocated					Oncology		Oncology		Corporate
		Solutions		Solutions		Corporate					Solutions		Solutions		Overhead
	Three Months Ended January 31, 2014	(POS)		(TOS)		Overhead		Consolidated			(POS)		(TOS)
	Net revenue	$	590	$	3,100	$	-	$	3,690	Net revenue	$	2,390	$	5,933	$	-	$	8,323
	Direct cost of services		-608		-1,007		-		-1,615	Direct cost of services		-2,604		-2,637		-		-5,241
	Sales and marketing costs		-405		-352		-		-757	Sales and marketing costs		-1,496		-938		-		-2,434
	Other operating expenses		-		-531		-1,254		-1,785	Other operating expenses		-134		-1,753		-2,606		-4,493
	Stock- based compensation expense (1)		-		-		-941		-941	Stock compensation expense (1)		-		-		-2,376		-2,376
	Segment profit (loss)	$	-423	$	1,210	$	-2,195	$	-1,408	Segment loss	$	-1,844	$	605	$	-4,982	$	-6,221
		Personalized		Translational						(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.
		Oncology		Oncology		Unallocated
		Solutions		Solutions		Corporate
	Nine Months Ended January 31, 2015	(POS)		(TOS)		Overhead		Consolidated
	Net revenue	$	1,245	$	4,377	$	-	$	5,622
	Direct cost of services		-2,171		-3,205		-		-5,376
	Sales and marketing costs		-1,243		-1,650		-		-2,893
	Other operating expenses		-		-3,490		-2,413		-5,903
	Stock- based compensation expense (1)		-		-		-2,284		-2,284
	Segment profit (loss)	$	-2,169	$	-3,968	$	-4,697	$	-10,834
		Personalized		Translational
		Oncology		Oncology		Unallocated
		Solutions		Solutions		Corporate
	Nine Months Ended January 31, 2014	(POS)		(TOS)		Overhead		Consolidated
	Net revenue	$	1,834	$	7,258	$	-	$	9,092
	Direct cost of services		-2,078		-2,572		-		-4,650
	Sales and marketing costs		-1,159		-812		-		-1,971
	Other operating expenses		-		-1,595		-2,790		-4,385
	Stock- based compensation expense (1)		-		-		-1,968		-1,968
	Segment profit (loss)	$	-1,403	$	2,279	$	-4,758	$	-3,882
	(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.

Redeemable_Common_Stock_and_St1

Redeemable Common Stock and Stock Purchase Warrants (Tables)	12 Months Ended
	Apr. 30, 2014
Redeemable Common Stock And Stock Purchase Warrant [Abstract]
Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]	Assumptions used to calculate the fair value of these warrants were as follows:
		Year Ended April 30,
		2014	2013
	Expected term in years	1.9 - 3.7	2.9 - 4.7
	Risk-free interest rates	0.4% - 1.17%	0.30%
	Volatility	95% - 113%	95% - 98%
	Dividend yield	0%	0%

Organization_Use_of_Estimates_2

Organization, Use of Estimates and Basis of Presentation (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2014	Apr. 30, 2013
Basic loss per share computation
Net loss attributable to common stockholders	($2,816,000)	($574,000)	($9,463,000)	($5,134,000)	($7,406,000)	($6,330,000)
Weighted Average common shares - basic	66,893,364	66,867,114	66,890,929	66,860,792
Basic net loss per share	($0.04)	($0.01)	($0.14)	($0.08)
Diluted loss per share computation
Net loss attributable to common stockholders	-2,816,000	-574,000	-9,463,000	-5,134,000	-7,406,000	-6,330,000
Less: Gain on derivative warrant liability	620,687	845,774	1,401,314	0
Loss available to common stockholders	($3,437,152)	($1,419,981)	($10,863,595)	($5,133,684)
Weighted Average common shares	66,893,364	66,867,114	66,890,929	66,860,792
Incremental shares from assumed exercise of warrants and stock options	352,213	0	352,213	0
Adjusted weighted average share - diluted.	67,245,577	66,867,114	67,243,142	66,860,792
Diluted net loss per share	($0.05)	($0.02)	($0.16)	($0.08)

Organization_Use_of_Estimates_3

Organization, Use of Estimates and Basis of Presentation (Details 1)	9 Months Ended		12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2014	Apr. 30, 2013
Total common stock equivalents	27,116,675	25,910,622	26,627,704	17,216,872
Restricted Stock [Member]
Total common stock equivalents			0	50,000
Warrant [Member]
Total common stock equivalents	3,126,667	3,276,667	3,276,667	3,276,667
Employee Stock Option [Member]
Total common stock equivalents	23,990,008	22,633,955

Organization_Use_of_Estimates_4

Organization, Use of Estimates and Basis of Presentation (Details Textual) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended		0 Months Ended
	Dec. 01, 2014	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2014	Apr. 30, 2013	Mar. 13, 2015	Mar. 11, 2015	Apr. 30, 2012
Cash and Cash Equivalents, at Carrying Value, Total		$182,000	$5,812,000	$182,000	$5,812,000	$5,891,000	$9,561,000			$4,754,000
Working Capital (Deficit)		4,700,000		4,700,000
Income Tax Expense (Benefit)		12,000	5,000	27,000	13,000	17,000	10,000
Term Of Warrants	5 years
Common Stock, Par or Stated Value Per Share		$0.00		$0.00		$0.00	$0.00
Subsequent Event [Member]
Unit Description								each unit consisting of one share of the Company's Common Stock, par value $0.001 per share (the "Common Stock"), and a warrant to buy 0.55 shares of Common Stock at $0.48 per share (the "Warrants"), at a purchase price of $0.40 per unit, for an aggregate of approximately$14,000,000.	each unit consisting of one share of the Company's common stock, par value $0.001 per share,and a warrant to buy 0.55 shares of common stock at $0.48 per share, at a purchase price of $0.40 per unit, for an aggregate of approximately$14,000,000
Aggregate Value Of Units Issued									$14,000,000
Subsequent Event [Member] | Common Stock [Member]
Common Stock, Par or Stated Value Per Share									$0.00
Shares Issued, Price Per Share									$0.48
Subsequent Event [Member] | Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right									0.55
Class of Warrant or Right, Exercise Price of Warrants or Rights									$0.40

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015	Apr. 30, 2014	Apr. 30, 2013
Balance end of year	($610)	($2,011)	($1,046)
Fair Value, Inputs, Level 3 [Member]
Balance beginning of year	-2,011	-1,046	-555
Transfers to (from) Level 3	0	0	0
Total gains (losses) included in earnings	1,401	-965	-74
Issuances	0	0	-417
Balance end of year		($2,011)	($1,046)

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1) (USD $)	Jan. 31, 2015	Apr. 30, 2014	Apr. 30, 2013
In Thousands, unless otherwise specified
Furniture and fixtures	$70	$69	$59
Computer equipment and software	694	655	549
Laboratory equipment	457	296	179
Leasehold improvements	2	2	2
Total property and equipment	1,223	1,022	789
Less: Accumulated depreciation	-754	-588	-375
Property and equipment, net	$469	$434	$414

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 2)	9 Months Ended		12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2014	Apr. 30, 2013
Total common stock equivalents	27,116,675	25,910,622	26,627,704	17,216,872
Warrant [Member]
Total common stock equivalents	3,126,667	3,276,667	3,276,667	3,276,667
Employee Stock Option [Member]
Total common stock equivalents			23,351,037	13,890,205
Restricted Stock [Member]
Total common stock equivalents			0	50,000

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2014	Apr. 30, 2013
Estimated Fair Value Of Warrants					$2,011,000	$1,046,000
Allowance for Doubtful Accounts Receivable					2,000	19,000
Unbilled Receivables, Current					884,000	200,000
Restricted Cash and Cash Equivalents, Noncurrent	163,000		163,000		165,000	192,000
Depreciation	52,000	56,000	166,000	158,000	213,000	203,000
Deferred Revenue					$258,000

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Jan. 31, 2015	Apr. 30, 2014	Apr. 30, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Furniture and fixtures	$70	$69	$59
Computer equipment and software	694	655	549
Laboratory equipment	457	296	179
Leasehold improvements	2	2	2
Total property and equipment	1,223	1,022	789
Less: Accumulated depreciation	-754	-588	-375
Property and equipment, net	$469	$434	$414

Property_and_Equipment_Details1

Property and Equipment (Details 1) (USD $)	Jan. 31, 2015
Capital Leased Assets [Line Items]
For the Years Ended April 30, 2015	$6
2016	23
2017	24
2018	25
2019	26
2020	16
Total minimum lease payments	120
Less: current maturity	-22
Long-term maturity	$98

Property_and_Equipment_Details2

Property and Equipment (Details Textual) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 30, 2014	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2014	Apr. 30, 2013
Property, Plant and Equipment [Line Items]
Depreciation		$52,000	$56,000	$166,000	$158,000	$213,000	$203,000
Monthly Capital Lease Payment	3,000
Capital Lease Minimum Lease Payment Percentage				5.00%
Capital Leased Assets, Gross		124,000		124,000		0
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation		6,000		6,000		0
Equipment Leased to Other Party [Member]
Property, Plant and Equipment [Line Items]
Capital Leases, Balance Sheet, Assets by Major Class, Net	$149,000

ShareBased_Payments_Details

Share-Based Payments (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2014	Apr. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$657	$941	$2,284	$1,968	$2,807	$2,376
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	474	866	1,530	1,686	2,298	1,984
Selling and Marketing Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	114	63	447	189	352	263
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	65	4	267	19	36	37
Translational Oncology Solutions Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	2	2	20	12	56	20
Personalized Oncology Solutions Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$2	$6	$20	$62	$65	$72

ShareBased_Payments_Details_1

Share-Based Payments (Details 1)	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2014	Apr. 30, 2013
Risk-free interest rates Minimum		1.40%	0.79%	0.80%	0.70%	0.70%
Risk-free interest rates Maximum		2.10%	1.94%	2.40%	2.40%	1.30%
Volatility Minimum		97.00%	85.80%	97.00%	84.00%	88.00%
Volatility Maximum		102.00%	102.10%	102.00%	102.00%	104.00%
Dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	0.00%
Minimum [Member]
Expected term in years		5 years	3 years	5 years	3 years	3 years
Maximum [Member]
Expected term in years		6 years	6 years	6 years	6 years	6 years

ShareBased_Payments_Details_2

Share-Based Payments (Details 2) (USD $)	9 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jan. 31, 2015	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Outstanding, Beginning Balance	23,351,037	13,890,205	14,866,038
Shares, Granted	1,093,175	9,793,332	741,250
Shares, Exercised	-3,750	-33,750	0
Shares, Canceled		0	-25,000
Shares, Forfeited	-101,250	-72,500	-551,250
Shares, Expired	-349,204	-226,250	-1,140,833
Shares, Outstanding, Ending Balance	23,990,008	23,351,037	13,890,205	14,866,038
Shares, Vested and expected to vest	23,990,008	23,351,037	13,890,205
Shares, Exercisable	17,031,966	13,564,577	11,344,454
Weighted Average Exercise Price, Outstanding, Beginning Balance	$1.01	$0.85	$0.88
Weighted Average Exercise Price, Granted	$0.72	$1.23	$0.41
Weighted Average Exercise Price, Exercised	$0.49	$0.63	$0
Weighted Average Exercise Price, Canceled		$0	$0.62
Weighted Average Exercise Price, Forfeited	$0.96	$0.82	$0.72
Weighted Average Exercise Price, Expired	$1.04	$0.73	$0.95
Weighted Average Exercise Price, Outstanding, Ending Balance	$1	$1.01	$0.85	$0.88
Weighted Average Exercise Price, Vested and expected to vest	$1
Weighted Average Exercise Price, Exercisable	$0.91	$0.85	$0.86
Weighted Average Remaining Contractual Term, Outstanding (in years)	6 years 7 months 6 days	7 years 6 months	7 years	7 years 7 months 6 days
Weighted Average Remaining Contractual Life (Years), Granted	5 years 10 months 24 days
Weighted Average Remaining Contractual Life (Years), Vested and expected to vest	6 years 7 months 6 days	7 years 6 months	7 years
Weighted Average Remaining Contractual Life (Years), Exercisable	5 years 9 months 18 days	6 years 1 month 6 days	6 years 10 months 24 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance	$985	$89,000	$0
Aggregate Intrinsic Value, Granted	0
Aggregate Intrinsic Value, Outstanding, Ending Balance	63	985	89,000	0
Aggregate Intrinsic Value, Vested and expected to vest	63	985,000	89,000
Aggregate Intrinsic Value, Exercisable	$62	$927,000	$54,000
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Outstanding, Beginning Balance	765,000	765,000	1,410,000
Shares, Granted	80,000	0	130,000
Shares, Exercised	0	0	0
Shares, Canceled		0	0
Shares, Forfeited	0	0	0
Shares, Expired	-150,000	0	-775,000
Shares, Outstanding, Ending Balance	695,000	765,000	765,000
Shares, Vested and expected to vest	695,000	765,000	765,000
Shares, Exercisable	487,500	522,292	458,334
Directors and Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Outstanding, Beginning Balance	22,586,037	13,125,205	13,456,038
Shares, Granted	1,013,175	9,793,332	611,250
Shares, Exercised	-3,750	-33,750	0
Shares, Canceled		0	-25,000
Shares, Forfeited	-101,250	-72,500	-551,250
Shares, Expired	-199,204	-226,250	-365,833
Shares, Outstanding, Ending Balance	23,295,008	22,586,037	13,125,205
Shares, Vested and expected to vest	23,295,008	22,586,037	13,125,205
Shares, Exercisable	16,544,466	13,042,285	10,886,120

ShareBased_Payments_Details_3

Share-Based Payments (Details 3) (USD $)	9 Months Ended	12 Months Ended
	Jan. 31, 2015	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2012
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance		50,000	25,000
Number of Shares, Granted		0	100,000
Number of Shares, Vested		-50,000	-75,000
Number of Shares, Forfeited		0	0
Number of Shares, Expired		0	0
Number of Shares, Ending Balance		0	50,000
Weighted Average Exercise Price, Beginning Balance		$0.30	$0.75
Weighted Average Exercise Price, Granted		$0	$0.30
Weighted Average Exercise Price, Vested		$0.30	$0.45
Weighted Average Exercise Price, Forfeited		$0
Weighted Average Exercise Price, Expired		$0
Weighted Average Exercise Price, Ending Balance		$0	$0.30
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance	3,276,667	3,276,667	1,416,667
Number of Shares, Granted	0	0	1,860,000
Number of Shares, Forfeited		0	0
Number of Shares, Exercised	0	0	0
Number of Shares, Expired	-150,000	0	0
Number of Shares, Ending Balance	3,126,667	3,276,667	3,276,667	1,416,667
Weighted Average Exercise Price, Beginning Balance	$0.61	$0.61	$0.50
Weighted Average Exercise Price, Granted	$0	$0	$0.66
Weighted Average Exercise Price, Forfeited		$0	$0
Weighted Average Exercise Price, Exercised	$0	$0	$0
Weighted Average Exercise Price, Expired	$0	$0	$0
Weighted Average Exercise Price, Ending Balance	$0.60	$0.61	$0.61	$0.50
Weighted Average Remaining Contractual Life (Years), Balance	2 years 3 months 18 days	2 years 10 months 24 days	3 years 10 months 24 days	3 years 9 months 18 days
Weighted Average Remaining Contractual Life (Years), Granted		0 years	4 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance	$984,000	$0	$0
Aggregate Intrinsic Value, Outstanding, Ending Balance	$0	$984,000	$0	$0

ShareBased_Payments_Details_4

Share-Based Payments (Details 4)	9 Months Ended	12 Months Ended
	Jan. 31, 2015	Apr. 30, 2014	Apr. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rates			0.30%
Dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term in years	1 year 2 months 12 days	1 year 10 months 24 days	2 years 10 months 24 days
Risk-free interest rates	0.60%	0.40%
Volatility	73.00%	95.00%	95.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term in years	3 years	3 years 8 months 12 days	4 years 8 months 12 days
Risk-free interest rates	1.05%	1.17%
Volatility	100.00%	113.00%	98.00%

ShareBased_Payments_Details_Te

Share-Based Payments (Details Textual) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended		1 Months Ended
	Dec. 12, 2013	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2014	Apr. 30, 2013	Feb. 18, 2011
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				1,093,175		9,793,332	741,250
Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding		3,276,667		3,276,667		3,276,667
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$0	$0.97	$0.67	$0.96	$0.96	$0.41
Warrants Not Settleable in Cash, Fair Value Disclosure		$600,000		$600,000		$2,010,000
Percentage Of Cash Penalties				1.00%		1.00%
Purchase Price Limit Percentage				10.00%		10.00%
Allocated Share-based Compensation Expense, Total		657,000	941,000	2,284,000	1,968,000	2,807,000	2,376,000
Stock Options Award Shares To Purchase Common Stock	200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value						15,000	34,000
Accrued Liabilities [Member]
Allocated Share-based Compensation Expense, Total				158,000
Minimum [Member]
Potential Penalties Amount				50,000		50,000
Maximum [Member]
Potential Penalties Amount				130,000		130,000
Equity Incentive Plan 2010 [Member]
Percentage Of Strike Price On Fair Market Value								100.00%
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures								30,000,000
Director Compensation Plan [Member]
Stock Options Award Shares To Purchase Unregistered Common Stock	20,000
Stock Options Award Shares To Purchase Common Stock	100,000
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Percentage	25.00%
Chief Executive Officer and President [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				3,000,000		3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total				3,000,000		3,000,000
April 2011 Private Placement [Member]
Warrants Issued During Period for Common Stock				1,266,667		1,266,667
April 2011 Private Placement [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$0.50		$0.50
April 2011 Private Placement [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$0.90		$0.90
January 2013 Private Placement [Member]
Warrants Issued During Period for Common Stock				1,860,000		1,860,000
Warrants and Rights Outstanding		$800,000		$800,000
Equity [Member]
Warrants Issued During Period for Common Stock				150,000		150,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$1		$1

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)	0 Months Ended	1 Months Ended		9 Months Ended		12 Months Ended
	Dec. 01, 2014	Jan. 28, 2013	Mar. 24, 2011	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2013	Apr. 30, 2014
Related Party Transaction, Amounts of Transaction				$75,000	$115,000
Debt Instrument, Term	90 days
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Debt Conversion, Converted Instrument, Rate	5.00%
Common Stock Purchase Price		$0.50	$0.75
Promissory Note Convertible [Member]
Debt Instrument, Face Amount	1,000,000
Private Placement [Member]
Stock Issued During Period, Shares, Issued for Services						1,000,000
Warrants Exercise Price Per Share						$0.50
Warrants Issued During Period For Common Stock						100,000
Common Stock Purchase Price						$0.66
Board of Directors Chairman [Member]
Related Party Transaction, Amounts of Transaction						160,000	150,000
Substantial Stockholders [Member]
Related Party Transaction, Amounts of Transaction						2,000	3,000
Board [Member]
Related Party Transaction, Amounts of Transaction							$15,800

Teva_Agreement_Details_Textual

Teva Agreement (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2014
Teva Agreement [Line Items]
Deferred Revenue, Revenue Recognized	$94,000	$0	$574,000	$194,000	$194,000

Fair_Value_Details

Fair Value (Details) (Fair Value, Inputs, Level 3 [Member], USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015	Apr. 30, 2014	Apr. 30, 2013
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, May 1, 2014	($2,011)
Transfers to (from) Level 3	0	0	0
Total gains (losses) included in earnings	1,401	-965	-74
Purchases, issuances and settlements, net	0	0	417
Balance, January 31, 2015	($610)	($2,011)

Significant_Customers_Details_

Significant Customers (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2014
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	10.00%
Customer One [Member]
Revenue, Major Customer [Line Items]
Revenues	1.6
Customer Two [Member]
Revenue, Major Customer [Line Items]
Revenues	1.5
Customer Three [Member]
Revenue, Major Customer [Line Items]
Revenues	1.5

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Apr. 30, 2014
In Thousands, unless otherwise specified
Operating Leased Assets [Line Items]
2015	$102,826
2016	85,185
2017	49,691
Total	$237,702

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual) (USD $)	9 Months Ended		12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2014	Apr. 30, 2013
Corporate Headquarters [Member]
Commitments and Contingencies [Line Items]
Lease Expiration Date	30-Nov-16		30-Nov-16
Operating Leases, Rent Expense	$64,000	$53,000	$75,000	$69,000
Laboratories and Office Space [Member]
Commitments and Contingencies [Line Items]
Lease Expiration Date	30-Jun-16		30-Jun-14
Operating Leases, Rent Expense	65,000	64,000	85,000	90,000
Israel Office Headquarters [Member]
Commitments and Contingencies [Line Items]
Lease Expiration Date	31-Jul-13
Operating Leases, Rent Expense	0	6,000	6,000	28,000
Singapore Office Headquarters in Singapore [Member]
Commitments and Contingencies [Line Items]
Lease Expiration Date	31-Jan-15		31-Jan-15
Operating Leases, Rent Expense	4,000	4,000	5,000	2,000
New York Laboratory [Member]
Commitments and Contingencies [Line Items]
Lease Expiration Date	30-Sep-15
Operating Leases, Rent Expense	$35,000

Redeemable_Common_Stock_and_St2

Redeemable Common Stock and Stock Purchase Warrants (Details)	9 Months Ended	12 Months Ended
	Jan. 31, 2015	Apr. 30, 2014	Apr. 30, 2013
Risk-free interest rates			0.30%
Dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Expected term in years	1 year 2 months 12 days	1 year 10 months 24 days	2 years 10 months 24 days
Risk-free interest rates	0.60%	0.40%
Volatility	73.00%	95.00%	95.00%
Maximum [Member]
Expected term in years	3 years	3 years 8 months 12 days	4 years 8 months 12 days
Risk-free interest rates	1.05%	1.17%
Volatility	100.00%	113.00%	98.00%

Redeemable_Common_Stock_and_St3

Redeemable Common Stock and Stock Purchase Warrants (Details Textual) (USD $)	1 Months Ended		9 Months Ended	12 Months Ended
	Jan. 28, 2013	Mar. 24, 2011	Jan. 31, 2015	Apr. 30, 2014	Apr. 30, 2013
Common Stock Purchase Price	$0.50	$0.75
Proceeds From Issuance Of Common Stock And Warrants	$9,100,000
Stock Issued During Period, Shares, Acquisitions	18,600,000	12,533,333
Stock Issued During Period, Value, Share-based Compensation, Gross	9,300,000	9,400,000
Stock Issued During Period, Value, Share-based Compensation, Forfeited	500,000	500,000
Estimated Fair Value Of Warrants				2,011,000	1,046,000
Percentage Of Cash Penalties			1.00%	1.00%
Purchase Price Limit Percentage			10.00%	10.00%
Maximum [Member]
Potential Penalties Amount			130,000	130,000
Minimum [Member]
Potential Penalties Amount			50,000	50,000
January 2013 Private Placement [Member]
Common Stock Purchase Price				$0.50
Proceeds From Issuance Of Common Stock And Warrants				9,300,000
Warrants Issued During Period For Common Stock				1,860,000
Warrants Exercise Price Per Share				$0.66
Percentage Of Common Stock Purchased				25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period				1,064,658
Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value				8,800,000
Proceeds from Issuance of Warrants				400,000
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost				200,000
Warrants and Rights Outstanding				800,000
April 2011 Private Placement [Member]
Common Stock Purchase Price				$0.75
Proceeds From Issuance Of Common Stock And Warrants				9,400,000
Warrants Issued During Period For Common Stock				1,266,667
Warrants Exercise Price Per Share				$0.90
Percentage Of Common Stock Purchased				25.00%
Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value				8,200,000
Proceeds from Issuance of Warrants				900,000
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost				$300,000
April 2011 Private Placement [Member] | Maximum [Member]
Warrants Exercise Price Per Share				$0.90
April 2011 Private Placement [Member] | Minimum [Member]
Warrants Exercise Price Per Share				$0.50

Provision_for_Income_Taxes_Det

Provision for Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014	Apr. 30, 2014	Apr. 30, 2013
Provision for Income Taxes, Current, Federal					$0	$0
Provision for Income Taxes, Current, State					5	2
Provision for Income Taxes, Current, Foriegn					12	8
Provision for Income Taxes, Current, Total					17	10
Provision for Income Taxes, Deferred, Federal					-2,015	-2,258
Provision for Income Taxes, Deferred, State					-148	-196
Provision for Income Taxes, Deferred, Foreign					0	0
Provision for Income Taxes, Deferred, Total					-2,163	-2,454
Provision for Income Taxes, Change in valuation allowance, Federal					2,015	2,258
Provision for Income Taxes, Change in valuation allowance, State					148	196
Provision for Income Taxes, Change in valuation allowance, Foreign					0	0
Provision for Income Taxes, Change in valuation allowance, Total					2,163	2,454
Provision for Income Taxes, Total, Federal					0	0
Provision for Income Taxes, Total, State					5	2
Provision for Income Taxes, Total, Foreign					12	8
Provision for Income Taxes, Total	$12	$5	$27	$13	$17	$10

Provision_for_Income_Taxes_Det1

Provision for Income Taxes (Details 1)	12 Months Ended
	Apr. 30, 2014	Apr. 30, 2013
Federal income tax at statutory rate	34.00%	34.00%
State income tax, net of federal benefit	2.10%	2.60%
Permanent differences	-5.60%	-0.50%
Other	-2.10%	1.60%
Change in valuation allowance	-27.20%	-39.60%
Changes in tax rates	-1.40%	1.70%
Income tax expense	-0.20%	-0.20%

Provision_for_Income_Taxes_Det2

Provision for Income Taxes (Details 2) (USD $)	Apr. 30, 2014	Apr. 30, 2013
In Thousands, unless otherwise specified
Accrued liabilities	$38	$89
Depreciation and amortization	9	51
State taxes	1	7
Stock-based compensation expense	4,511	3,582
Capitalized research and development costs	556	688
Foreign net operating loss carry-forward	244	386
Net operating loss carry-forward	5,608	4,144
Total deferred tax assets	10,968	8,948
Less: Valuation allowance	-10,968	-8,948
Net deferred tax asset	$0	$0

Provision_for_Income_Taxes_Det3

Provision for Income Taxes (Details Textual) (USD $)	12 Months Ended
	Apr. 30, 2014	Apr. 30, 2013
Deferred Tax Assets, Valuation Allowance	10,968,000	$8,948,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards	15,426,000	11,216,000
Foreign Tax Authority [Member]
Operating Loss Carryforwards	1,034,000	$1,744,000
State and Local Jurisdiction [Member]
Operating Loss Carry Forwards Expiration Year	begin expiring in 2029.

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended				9 Months Ended				12 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015		Jan. 31, 2014		Jan. 31, 2015		Jan. 31, 2014		Apr. 30, 2014		Apr. 30, 2013
Net revenue	$1,829		$3,690		$5,622		$9,092		$11,550		$8,323
Sales and marketing costs	-1,094		-821		-3,340		-2,160		-3,155		-2,665
Stock- based compensation expense	-657		-941		-2,284		-1,968		-2,807		-2,376
Personalized Oncology Solutions [Member]
Net revenue	453		590		1,245		1,834		2,264		2,390
Direct cost of services	-672		-608		-2,171		-2,078		-2,667		-2,604
Sales and marketing costs	-366		-405		-1,243		-1,159		-1,723		-1,496
Other operating expenses	0		0		0		0		0		-134
Stock- based compensation expense	0	[1]	0	[1]	0	[1]	0	[1]	0	[1]	0	[1]
Segment profit (loss)	-585		-423		-2,169		-1,403		-2,126		-1,844
Translational Oncology Solutions [Member]
Net revenue	1,376		3,100		4,377		7,258		9,286		5,933
Direct cost of services	-1,300		-1,007		-3,205		-2,572		-3,496		-2,637
Sales and marketing costs	-613		-352		-1,650		-812		-1,080		-938
Other operating expenses	-1,028		-531		-3,490		-1,595		-2,209		-1,753
Stock- based compensation expense	0	[1]	0	[1]	0	[1]	0	[1]	0	[1]	0	[1]
Segment profit (loss)	-1,565		1,210		-3,968		2,279		2,501		605
Unallocated Corporate Overhead [Member]
Net revenue	0		0		0		0		0		0
Direct cost of services	0		0		0		0		0		0
Sales and marketing costs	0		0		0		0		0		0
Other operating expenses	-612		-1,254		-2,413		-2,790		-3,828		-2,606
Stock- based compensation expense	-657	[1]	-941	[1]	-2,284	[1]	-1,968	[1]	-2,807	[1]	-2,376	[1]
Segment profit (loss)	-1,269		-2,195		-4,697		-4,758		-6,635		-4,982
Consolidated [Member]
Net revenue	1,829		3,690		5,622		9,092		11,550		8,323
Direct cost of services	-1,972		-1,615		-5,376		-4,650		-6,163		-5,241
Sales and marketing costs	-979		-757		-2,893		-1,971		-2,803		-2,434
Other operating expenses	-1,640		-1,785		-5,903		-4,385		-6,037		-4,493
Stock- based compensation expense	-657	[1]	-941	[1]	-2,284	[1]	-1,968	[1]	-2,807	[1]	-2,376	[1]
Segment profit (loss)	($3,419)		($1,408)		($10,834)		($3,882)		($6,260)		($6,221)
[1]	Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)	0 Months Ended	9 Months Ended	1 Months Ended	12 Months Ended	0 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 01, 2014	Jan. 31, 2015	Mar. 24, 2011	Apr. 30, 2013	Mar. 13, 2015	Mar. 11, 2015	Jan. 28, 2013
Subsequent Event [Line Items]
Debt Conversion, Original Debt, Amount	$1
Term Of Warrants	5 years
Repurchase Of Stock In Put Option		$0.40
2011 Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues			1,865,853
Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues				1,064,658
Subsequent Event [Member]
Subsequent Event [Line Items]
Unit Description					each unit consisting of one share of the Company's Common Stock, par value $0.001 per share (the "Common Stock"), and a warrant to buy 0.55 shares of Common Stock at $0.48 per share (the "Warrants"), at a purchase price of $0.40 per unit, for an aggregate of approximately$14,000,000.	each unit consisting of one share of the Company's common stock, par value $0.001 per share,and a warrant to buy 0.55 shares of common stock at $0.48 per share, at a purchase price of $0.40 per unit, for an aggregate of approximately$14,000,000
Subsequent Event [Member] | 2011 Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Additional Warrants Issued to Investors			1,583,335
Warrant Exercise Price			0.4
Additional Common Stock And Warrants Issued to Investors			2,264,450
Subsequent Event [Member] | 2013 Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Additional Warrants Issued to Investors							1,209,001
Warrant Exercise Price							$0.40